<SEC-DOCUMENT>0001140361-23-009749.txt : 20230302
<SEC-HEADER>0001140361-23-009749.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302161802
ACCESSION NUMBER:		0001140361-23-009749
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		23699192

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>brhc10049211_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" style="border-width: 4px medium 1px; border-style: solid none; border-color: black currentColor; border-image: none; height: 10px; text-align: center; color: rgb(255, 255, 255); margin-right: auto; margin-left: auto; background-color: rgb(255, 255, 255);">
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
        <div>&#160;
          <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);"></div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
          <div><br>
          </div>
          <div style="font-size: 18pt;">FORM 8-K</div>
          <div><br>
          </div>
          <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
        <div>&#160;</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CURRENT REPORT</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pursuant to Section 13 or 15(d)</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">of the Securities Exchange Act of 1934</div>
        <div>&#160;</div>
        <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="color: rgb(0, 0, 0); font-size: 10pt;">Date of Report (Date of earliest event reported): February 27, 2023</font></div>
        <div>&#160;
          <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);"></div>
        <div style="text-align: center; font-size: 24pt;"><font style="font-weight: bold;">CATALYST BIOSCIENCES, INC.</font></div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><br>
        </div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
          <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);"></div>
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="zfd93428d92c24c92824d8b93569ebacc">

            <tr>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware<br>
                </div>
              </td>
              <td style="width: 1.76%; vertical-align: bottom;">&#160;</td>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">000-51173<br>
                </div>
              </td>
              <td style="width: 1.76%; vertical-align: bottom;">&#160;</td>
              <td style="width: 31.52%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">56-2020050<br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or other jurisdiction of incorporation)</div>
              </td>
              <td style="width: 1.76%; vertical-align: bottom;">&#160;</td>
              <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Commission File Number)</div>
              </td>
              <td style="width: 1.76%; vertical-align: bottom;">&#160;</td>
              <td style="width: 31.52%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(IRS Employer Identification No.)</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">611 Gateway Blvd, Suite 120, South San Francisco, CA 94080</div>
        <div style="text-align: center; font-weight: bold;">(Address of principal executive offices)</div>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">(650) 871-0761</div>
        <div style="text-align: center; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">Not Applicable</div>
        <div style="text-align: center;">(<font style="font-weight: bold;">Former name or former address, if changed since last report.)</font></div>
        <div>&#160;</div>
        <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="zc544417ad1d44a74ac8ed0d0075b735a" class="DSPFListTable">

            <tr>
              <td style="width: 22.5pt; vertical-align: top;">&#9744;<br>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -22.5pt; margin-left: 22.5pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="za23637787d6a47149eeceb6a674df7be" class="DSPFListTable">

            <tr>
              <td style="width: 22.5pt; vertical-align: top;">&#9746;<br>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -22.5pt; margin-left: 22.5pt;"><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zbce11bbd72c747b5a8ce17fe1fdcc2bd" class="DSPFListTable">

              <tr style="vertical-align: top;">
                <td style="width: 22.5pt; vertical-align: top;">&#9744;<br>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="text-align: left; text-indent: -22.5pt; margin-left: 22.5pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-indent: -22.5pt; margin-left: 22.5pt;"><br>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zde38a10eb1c043868ad05ddaf50a03da" class="DSPFListTable">

              <tr style="vertical-align: top;">
                <td style="width: 22.5pt; vertical-align: top;">&#9744;<br>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="text-align: left; text-indent: -22.5pt; margin-left: 22.5pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
                </td>
              </tr>

          </table>
        </div>
        <div>&#160;</div>
        <div>Securities registered pursuant to Section 12(b) of the Act:</div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="zb7d7e95a06424bd9a0baefda4adc441d">

            <tr>
              <td style="border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0); width: 33%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">Title of each class</div>
              </td>
              <td style="border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0); width: 34%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
              </td>
              <td style="border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0); width: 33%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
              </td>
            </tr>
            <tr>
              <td style="border-width: 1px 2px 2px; border-style: solid; border-color: rgb(0, 0, 0); width: 33%; vertical-align: top;">
                <div style="text-align: center;">Common Stock<br>
                </div>
              </td>
              <td style="border-width: 1px 2px 2px; border-style: solid; border-color: rgb(0, 0, 0); width: 34%; vertical-align: top;">
                <div style="text-align: center;">CBIO<br>
                </div>
              </td>
              <td style="border-width: 1px 2px 2px; border-style: solid; border-color: rgb(0, 0, 0); width: 33%; vertical-align: top;">
                <div style="text-align: center;">Nasdaq<br>
                </div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (<font style="color: rgb(0, 0, 0);">&#167;</font> 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
          of 1934 (<font style="color: rgb(0, 0, 0);">&#167;</font> 240.12b-2 of this chapter).</div>
        <div>&#160;</div>
        <div>Emerging growth company &#9744;</div>
        <div>&#160;</div>
        <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
          Exchange Act. &#9744;</div>
        <div><br>
        </div>
        <div>
          <hr align="center" style="border-width: 1px medium 4px; border-style: solid none; border-color: black currentColor; border-image: none; height: 10px; text-align: center; color: rgb(255, 255, 255); margin-right: auto; margin-left: auto; background-color: rgb(255, 255, 255);"></div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
        </div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="z7880cb51f5d04b09a4197f1114fbe04f" class="DSPFListTable">

            <tr>
              <td style="width: 45pt; color: rgb(0, 0, 0); font-weight: bold; vertical-align: top;">Item 1.01</td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Entry into a Material Definitive Agreement.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div><font style="color: rgb(0, 0, 0);">On February 27, 2023, Catalyst Biosciences, Inc. (&#8220;Catalyst&#8221;) entered into and closed on an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with GC Biopharma Corp. (&#8220;Buyer&#8221;), pursuant to which Buyer
            acquired on such date Catalyst&#8217;s legacy rare bleeding disorder program,</font>&#160;<font style="color: rgb(0, 0, 0);">including marzeptacog alpha activated (MarzAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the &#8220;Purchased Assets&#8221;).</font></div>
        <div><br>
        </div>
        <div style="color: rgb(0, 0, 0);">In consideration for the purchase of the Purchased Assets, Buyer will pay Catalyst a total of $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back until twenty-four months
          after the closing, subject to the satisfaction of post-closing indemnification obligations. The Purchase Agreement includes customary representations, warranties, covenants and indemnification provisions. Once received, the net proceeds from the
          transaction will be distributed to holders of the contingent value right issued to Catalyst stockholders of record on January 5, 2023.</div>
        <div><br>
        </div>
        <div><font style="color: rgb(0, 0, 0);">The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit </font>10.1&#167;<font style="color: rgb(0, 0, 0);"> to this Current Report on Form 8-K and is incorporated herein by reference.</font></div>
        <div><br>
        </div>
        <div style="color: rgb(0, 0, 0);">The Purchase Agreement has been included to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about Catalyst or Buyer. The
          Purchase Agreement contains representations, warranties and covenants that Catalyst and Buyer made to each other as of specific dates. The assertions embodied in those representations, warranties and covenants were made solely for purposes of the
          Purchase Agreement between Catalyst and Buyer and may be subject to important qualifications and limitations agreed to by Catalyst and Buyer in connection with negotiating its terms, including being qualified by confidential disclosures exchanged
          between the parties in connection with the execution of the Purchase Agreement. The representations and warranties may be subject to a contractual standard of materiality that may be different from what may be viewed as material to investors or
          securityholders or may have been used for the purpose of allocating risk between Catalyst and Buyer rather than establishing matters as facts. Moreover, information concerning the subject matter of the representations and warranties may change
          after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in Catalyst&#8217;s public disclosures. For the foregoing reasons, no person should rely on the representations and warranties as statements of
          factual information at the time they were made or otherwise.</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="z501d5a9ff75941a789b7e102173e6392" class="DSPFListTable">

            <tr>
              <td style="width: 45pt; font-weight: bold; vertical-align: top;">Item 2.01</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Completion of Acquisition or Disposition of Assets.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div>The information set forth in Item 1.01 above is incorporated by reference into this Item 2.01.</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="zbdd85dd42b634efa9c17817a840927e1" class="DSPFListTable">

            <tr>
              <td style="width: 45pt; font-weight: bold; vertical-align: top;">Item 8.01</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Other Events.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div>In connection with Catalyst&#8217;s previously announced asset purchase agreement with GNI Group Ltd. (&#8220;GNI Group&#8221;) and GNI Hong Kong Limited (together with GNI Group, &#8220;GNI&#8221;) to purchase all of the assets and intellectual property rights primarily
          related to GNI&#8217;s proprietary hydronidone compound outside of China (collectively, the &#8220;F351 Assets&#8221;), and the definitive agreement with GNI and other minority stockholders to purchase their controlling interest in Beijing Continent
          Pharmaceuticals Co., Ltd., a commercial-stage pharmaceutical company (the &#8220;GNI Transactions&#8221;), GNI Group reported its Consolidated Financial Results for its Fiscal Year 2022 on February 15, 2023, showing continued revenue and profit growth from
          pirfenidone sales in China for the treatment of idiopathic pulmonary fibrosis&#160;which includes revenue of approximately $102 million and net profit of approximately $23 million. A copy of GNI Group&#8217;s financial results is available on the GNI Group
          investor relations website: https://www.gnipharma.com/english/ir/.</div>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
        </div>
        <div style="font-weight: bold;">Forward-Looking Statements</div>
        <div>&#160;</div>
        <div>This Current Report on Form 8-K and the exhibits furnished herewith contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of
          1933, as amended (the &#8220;Securities Act&#8221;)) concerning Catalyst, GNI, the GNI Transactions, and potential future payments and distributions from the sale of the Purchased Assets to Buyer. These statements may discuss goals, intentions and
          expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Catalyst, as well as assumptions made by, and information currently available to,
          management of Catalyst. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions that are predictions or indicate future events or prospects, involve risks and
          uncertainties and include, but are not limited to, expectations regarding: the GNI Transactions; the potential of, and expectations regarding, GNI&#8217;s programs; the potential for an additional $5 million payment from Buyer; and the distribution of
          cash to legacy Catalyst stockholders. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation:(i)
          uncertainties as to the timing of the GNI Transactions; (ii) risk that future payments from Buyer will be reduced by indemnification claims under Catalyst&#8217;s agreement with Buyer; (iii) risks related to Catalyst&#8217;s ability to manage its operating
          expenses and expenses associated with the GNI Transactions; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions
          contemplated by the GNI Transactions; (v) unexpected costs, charges or expenses resulting from the purchase of the F351 Assets; (vi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of
          the GNI Transactions; (vii) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the product candidates and preclinical programs of Catalyst; and (viii) risks associated with the
          possible failure to realize certain anticipated benefits of the GNI Transactions, including with respect to future financial and operating results. These and other risks and uncertainties are more fully described in periodic filings with the SEC,
          including the risk factors included in Catalyst&#8217;s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) as well as the proxy statement and
          registration statement on Form S-3 to be filed with the SEC by Catalyst. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking
          statements. Except as required by law, Catalyst expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in
          events, conditions or circumstances on which any such statements are based.</div>
        <div>&#160;</div>
        <div style="font-weight: bold;">No Offer or Solicitation</div>
        <div>&#160;</div>
        <div>This Current Report on Form 8-K is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in
          any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a
          prospectus meeting the requirements of the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any
          jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, telephone and the internet) of interstate or foreign commerce, or
          any facility of a national securities exchange, of any such jurisdiction.</div>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
        </div>
        <div>
          <div style="font-weight: bold;">Important Additional Information Will be Filed with the SEC</div>
          <div>&#160;</div>
          <div>In connection with the proposed transactions between Catalyst and GNI, Catalyst intends to file relevant materials with the SEC, including a proxy statement and registration statement on Form S-3 that will contain a prospectus of Catalyst.
            CATALYST URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CATALYST, GNI, THE GNI TRANSACTIONS AND RELATED MATTERS.
            Investors and stockholders will be able to obtain free copies of the proxy statement and prospectus and other documents filed by Catalyst with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In
            addition, investors and stockholders will be able to obtain free copies of the proxy statement and prospectus and other documents filed by Catalyst with the SEC by contacting Catalyst Biosciences, Inc. at 611 Gateway Blvd. Suite 120, South San
            Francisco, California 94080. Investors and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed
            transactions.</div>
          <div>&#160;</div>
          <div style="font-weight: bold;">Participants in the Solicitation</div>
          <div><br>
          </div>
        </div>
        <div>
          <div>Catalyst, GNI and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transactions. Information about Catalyst&#8217;s directors and executive officers is
            included in Catalyst&#8217;s most recent Annual Report on Form 10-K, including any information incorporated therein by reference, as filed with the SEC, the proxy statement for Catalyst&#8217;s 2022 annual meeting of stockholders, and Catalyst&#8217;s Form 8-K
            filed with the SEC on December 27, 2022. Additional information regarding the persons who may be deemed participants in the solicitation of proxies will be included in the proxy statement and prospectus relating to the proposed transactions
            when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.</div>
          <div>&#160;</div>
        </div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="zbca761988c3546ea910a3ff5fa832fe5" class="DSPFListTable">

            <tr>
              <td style="width: 45pt; font-weight: bold; vertical-align: top;">Item 9.01</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div>(b)&#160; Pro Forma Financial Information</div>
        <div>&#160;</div>
        <div>(d)&#160; Exhibits</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="z7daada632c8b44e69638f94c08457842">

            <tr>
              <td style="border-bottom: 2px solid #000000; vertical-align: middle; white-space: nowrap; width: 6.57%;">
                <div style="text-align: center; font-weight: bold;">Exhibit No.</div>
              </td>
              <td style="width: 3.36%; vertical-align: middle;">&#160;</td>
              <td style="width: 83.78%; vertical-align: middle; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">
                <div style="font-weight: bold;">Description</div>
              </td>
              <td style="width: 6.3%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 6.57%; vertical-align: top;">
                <div style="text-align: center;">10.1&#167;</div>
              </td>
              <td style="width: 3.36%; vertical-align: top;">&#160;</td>
              <td colspan="2" style="width: 90.07%; vertical-align: top;">
                <div style="margin-right: 63pt;">Asset Purchase Agreement dated as of February 27, 2023 by and between Catalyst Biosciences, Inc. and <font style="color: rgb(0, 0, 0);">GC Biopharma Corp</font>. <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 6.57%; vertical-align: top;">
                <div style="text-align: center;">99.1</div>
              </td>
              <td style="width: 3.36%; vertical-align: top;">&#160;</td>
              <td colspan="2" style="width: 90.07%; vertical-align: top;">
                <div style="margin-right: 63pt;">Press Release of Catalyst Biosciences, Inc. dated February 28, 2023.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 6.57%; vertical-align: top;">
                <div style="text-align: center;">104</div>
              </td>
              <td style="width: 3.36%; vertical-align: top;">&#160;</td>
              <td colspan="2" style="width: 90.07%; vertical-align: top;">
                <div style="margin-right: 63pt;">Cover Page Interactive Data File (formatted as Inline XBRL document).</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="zfd23163107b444d49e18ca1bd7a5128e" class="DSPFListTable">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#167;</td>
              <td style="width: auto; vertical-align: top;">
                <div>Portions of this exhibit (indicated by &#8220;[***]&#8221;) have been redacted in accordance with Regulation S-K Item 601(b)(10)(iv).</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
        </div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SIGNATURES</div>
        <div>&#160;</div>
        <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="z994867b5007b4b478c1d2a22c782b7be">

            <tr>
              <td style="width: 50.36%; vertical-align: top;">&#160;</td>
              <td style="width: 49.64%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">CATALYST BIOSCIENCES, INC.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.36%; vertical-align: middle;">&#160;</td>
              <td style="width: 49.64%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50.36%; vertical-align: top;">
                <div>Date: March 2, 2023</div>
              </td>
              <td style="width: 49.64%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid;">
                <div>
                  <div>/s/ Nassim Usman</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.36%; vertical-align: top;">&#160;</td>
              <td style="width: 49.64%; vertical-align: bottom;">
                <div>Nassim Usman, Ph.D.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.36%; vertical-align: top;">&#160;</td>
              <td style="width: 49.64%; vertical-align: bottom;">
                <div>President and Chief Executive Officer</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div>
          <div>
            <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
            <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.1</font><br>
            </div>
            <div><font style="font-weight: bold;"> <br>
              </font></div>
            <div>Certain information identified by bracketed asterisks ([***]) has been omitted from this exhibit because it is both not material and would be competitively harmful if publicly disclosed.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;"><u>ASSET PURCHASE AGREEMENT</u></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">THIS ASSET PURCHASE AGREEMENT </font>(this &#8220;<u>Agreement</u>&#8221;) is entered into as of this<font style="font-weight: bold;">&#160;</font>27th day of February, 2023,
              by and among (i) GC Biopharma Corp., a Yongin-si corporation (the &#8220;<u>Buyer</u>&#8221;), and (ii) Catalyst Biosciences, Inc., a Delaware corporation<font style="font-weight: bold;"> (</font>the &#8220;<u>Seller</u>&#8221;).&#160; The Buyer and the Seller are
              sometimes referred to herein individually as a &#8220;<u>Party</u>&#8221; and collectively as the &#8220;<u>Parties</u>&#8221;.&#160; The capitalized terms used herein and not otherwise defined herein have the meanings given to such terms as set forth in <u>Appendix A</u>
              hereto.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">RECITALS</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, the Seller operates a business engaged in, among other things, the development and commercialization of the Products;<font style="font-weight: bold;">&#160;</font>and</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, upon the terms and subject to the conditions set forth herein, the Buyer desires to purchase from the Seller, and the Seller desires to sell
              to the Buyer, certain assets of the Seller in exchange for the consideration set forth herein.</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">NOW, THEREFORE</font>, in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties,
              covenants and agreements herein contained, the Parties agree as follows:</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">ARTICLE I</div>
            <div style="text-align: center; font-weight: bold;">PURCHASE AND SALE OF PURCHASED ASSETS</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Purchased Assets</u>.&#160; At the Closing, on the terms and subject to the conditions of this Agreement, and on the basis of the representations, warranties, covenants and
              agreements herein contained, the Seller (and will cause each other Seller Party to) sell, convey, assign, transfer and deliver to the Buyer, and the Buyer will purchase, accept and take from the Seller, all of the right, title and interest
              in, to and under the Purchased Assets, free and clear of any Encumbrances.</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Excluded Assets</u>.&#160; Notwithstanding that any assets or other rights would otherwise be included in the Purchased Assets, at the Closing, on the terms and subject to the
              conditions of this Agreement, and on the basis of the representations, warranties, covenants and agreements herein contained, the Seller will (and will cause each other Seller Party to) not sell, convey, assign, transfer or deliver to the
              Buyer, and the Buyer will not purchase, accept or take from Seller, any Excluded Assets.&#160; &#8220;<u>Excluded Assets</u>&#8221; means any asset, property, privilege, claim, title, interest, or right of Seller that is not specifically included in the
              Purchased Assets (all such excluded assets, the &#8220;<u>Excluded Assets</u>&#8221;).</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Excluded Liabilities</u>.&#160; Except as expressly set forth in <u>Section 1.4</u>, the Buyer shall not assume, whether as a transferee or successor, by contract, operation of
              law or otherwise, and the Seller shall remain liable for, any and all Liabilities or Encumbrances of the Seller.&#160; The Buyer shall not assume or be responsible for any of the Excluded Liabilities.</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <!--PROfilePageNumberReset%Num%2%-%-%-->
            <div style="text-align: justify; text-indent: 36pt;">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assumption of Certain Liabilities</u>.&#160; At the Closing, subject to the terms and conditions set forth herein, the Buyer shall assume and agree to pay, perform, honor and
              discharge when due only the Liabilities arising under or relating to the Assumed Contracts; provided, however, the Seller shall be responsible for payments due under the Assumed Contracts through February 28, 2023 and the Buyer shall assume
              payment obligations under the Assumed Contracts beginning on March 1, 2023, but, in each case, only to the extent that such Liabilities do not relate to any breach, default or violation by any Seller Party on or prior to the Closing
              (collectively, the &#8220;<u>Assumed Liabilities</u>&#8221;).&#160; <font style="color: rgb(0, 0, 0);">Notwithstanding any provision in this Agreement or any of the other Transaction Agreements to the contrary, the Buyer shall not assume or be deemed to have
                assumed any Liabilities of the Seller</font>&#160;<font style="color: rgb(0, 0, 0);">(or any predecessor owner of all or part of the Seller&#8217;s business or assets), including those Liabilities that would become Liabilities of the Buyer as a matter
                of Law in connection with this Agreement, the other Transaction Agreements and the transactions contemplated hereby and thereby, other than the Assumed Liabilities.</font></div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">1.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Purchase Price</u>.&#160; Subject to the adjustments set forth in <u>Section 1.6</u> and <u>Article II</u>, in consideration for the sale, conveyance, assignment, transfer and
              delivery to the Buyer of the Purchased Assets and Buyer&#8217;s assumption of the Assumed Liabilities, the Buyer shall pay to the Seller the Purchase Price by wire transfer in immediately available funds.</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">1.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Withholding of Tax</u>.&#160; Notwithstanding anything in this Agreement to the contrary, the Buyer and its Affiliates are entitled to withhold or otherwise deduct from the
              consideration otherwise payable pursuant to this Agreement such amounts as the Buyer (or any Affiliate thereof) determines in good faith to be required under any provision of Tax Law.&#160; If the Buyer or its Affiliate determines that such
              deduction or withholding is so required, it shall provide written notice of such intent to withhold on or prior to five (5) days prior to the Closing Date and shall cooperate with the Seller and the Business to the extent that such
              cooperation may reduce or eliminate any such deduction or withholding, including the collection and/or filing of any applicable tax forms, documents or information.&#160; To the extent that amounts are so withheld by the Buyer or any of its
              Affiliates, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the payee with respect to which such amount was withheld.</div>
            <div style="text-indent: 36pt;">&#160;</div>
            <div>
              <div style="text-align: center; font-weight: bold;">ARTICLE II</div>
              <div style="text-align: center; font-weight: bold;">CLOSING</div>
              <div>&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Time and Place of the Closing</u>.&#160; The Closing shall take place remotely by exchange of documents and signatures on the date of this Agreement by electronic delivery of
              documents (by &#8220;portable document format&#8221;, email, or other form of electronic communication) all of which will be deemed to be originals.&#160; The Closing will be deemed to have occurred at 12:01 a.m. Eastern Time on the date of this Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing Deliverables</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Seller Deliverables</u>.&#160; At the Closing, the Seller shall have delivered to the Buyer:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a certificate of its secretary, setting forth the certified organizational documents (as in effect immediately prior to the Closing) and resolutions of its Board of Directors
              authorizing the execution, delivery and performance of this Agreement and the other documents contemplated hereby and the consummation of the transactions contemplated hereby and thereby, and certifying that such organizational documents and
              resolutions have not been amended or rescinded and are in full force and effect;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a good standing certificate from the jurisdiction of its incorporation;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">duly executed counterparts to this Agreement and all other Transaction Agreements to which the Seller&#160;is a party;</font></div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-2-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Bill of Sale, Assignment and Assumption Agreement in the form attached hereto as <u>Exhibit A</u>;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a duly executed IRS Form W-9;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">[***]&#160;&#160;&#160;&#160;&#160; [***];</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; such other bills of sale, deeds, assignments, certificates of title and other documents of transfer as may be reasonably requested by the Buyer in order to convey to the Buyer
              good and marketable title to all of the Purchased Assets, free and clear of all Encumbrances, and in order to carry out the intentions and purposes of this Agreement and the other documents contemplated hereby.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Buyer Deliverables</u>.&#160; At the Closing, the Buyer shall have delivered to the Seller, duly executed counterparts to this Agreement and all other Transaction Agreements to
              which the Buyer&#160;is a party.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Payments</u>.&#160; the Buyer shall pay to the Seller:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the time of Closing, an amount in cash equal to (i)&#160;the Purchase Price, <u>minus</u> (ii) the Holdback Amount (such amount, the &#8220;<u>Closing Payment</u>&#8221;), by wire transfer of
              immediately available funds to the account designated on <u>Schedule 2.3(a)</u> (&#8220;<u>Seller Account</u>&#8221;); and</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Within [***], an amount in cash equal to Seller&#8217;s aggregate expenses for which an invoice has been submitted on or before the Closing set forth on <u>Schedule 2.3(b)</u>, by
              wire transfer of immediately available funds to the Seller Account.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">ARTICLE III</div>
            <div style="text-align: center; font-weight: bold;">REPRESENTATIONS AND WARRANTIES RELATING TO THE SELLER</div>
            <div>&#160;</div>
            <div style="text-align: justify;">As a material inducement to the Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, except as set forth in the corresponding sections or subsections of the disclosure
              schedule attached hereto (the &#8220;<u>Disclosure Schedule</u>&#8221;), the Seller represents and warrants to the Buyer as of the date of this Agreement and as of Closing Date as follows:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Organization and Qualification</u>.&#160; The Seller is a corporation, duly organized, validly existing and in good standing under the Laws of the State of Delaware <font style="color: rgb(0, 0, 0);">and has the requisite </font>corporate <font style="color: rgb(0, 0, 0);">power and authority to carry on its business as it is now being conducted and as currently proposed to be conducted</font>.&#160; The Seller
              is qualified or registered to do business and is in good standing <font style="color: rgb(0, 0, 0);">(to the extent such concept or a comparable status is recognized) </font>in each other jurisdiction where the nature of the Business
              requires such qualification or registration, except where the failure to be so qualified, registered or in good standing would not reasonably be expected to result in an adverse effect on the Business or the Purchased Assets.&#160; The Seller has
              not conducted any business under or otherwise used, for any purpose or in any jurisdiction, any fictitious name, assumed name, trade name or other name.&#160; The Seller is not in violation of the provisions of its organizational documents.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-3-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.2&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority for Agreement</u>.&#160; The Seller has full corporate power and authority to enter into and perform its obligations under this Agreement and the other documents
              contemplated hereby to which the Seller is or will be a party and to consummate the transactions contemplated hereby and thereby.&#160; The stockholders and <font style="color: rgb(0, 0, 0);">the board of directors </font>of the Seller have duly
              authorized the execution, delivery and performance of this Agreement and the other documents contemplated hereby and the consummation of the transactions contemplated hereby and thereby.&#160; No other corporate action on the part of any Seller
              Party or any stockholder, director or other equityholder or governing body of any Seller Party is necessary to approve and authorize the execution, delivery and performance of this Agreement and the other documents contemplated hereby and the
              consummation of the transactions contemplated hereby and thereby.&#160; This Agreement and the other documents contemplated hereby have been duly executed and delivered by the Seller and assuming the due execution and delivery by the Buyer hereto
              and thereto, are legal, valid and binding obligations of the Seller, enforceable against the respective party in accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency,
              reorganization, moratorium or other similar Laws affecting the enforcement of creditors&#8217; rights in general and general principles of equity.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Violation to Result</u>.&#160; The execution, delivery and performance by the Seller of this Agreement and the other documents contemplated hereby and the consummation by the
              Seller of the transactions contemplated hereby and thereby and the fulfillment by the Seller of the terms hereof and thereof, do not and will not:&#160; (a) violate, breach or constitute a default under (or event which, with the giving of notice
              or lapse of time, or both, would become a default under), accelerate or permit the acceleration of the performance required by: (i) any of the terms of the organizational documents, or any resolution adopted by any of the shareholders or
              directors of any Seller Party, or (ii) any Contract related to the Business or otherwise Affecting the Purchased Assets; (b) give any Person the right to declare a default or exercise any remedy or accelerate performance or maturity under any
              Contract related to the Business or otherwise Affecting the Purchased Assets or cancel, terminate or modify any Contract related to the Business or otherwise Affecting the Purchased Assets; (c)&#160; give any Governmental Authority or other Person
              the right to prohibit any of the transactions contemplated by this Agreement; or (d) give any Governmental Authority the right to revoke, withdraw, suspend, cancel, modify or terminate any permit, license, or designation that is held by any
              Seller Party or that is otherwise necessary for any Seller Party to conduct the Business or to own the Purchased Assets.&#160; No notice to, filing with, or consent of, any Person is necessary in connection with, and no &#8220;change of control&#8221;
              provision in any Contract related to the Business or otherwise Affecting the Purchased Assets is, or will be, triggered by, the authorization, approval, execution, delivery or performance by the Seller of this Agreement and the other
              documents contemplated hereby or the consummation by the Seller of the transactions contemplated hereby or thereby.&#160; Each Seller Party has given all notices, made all filings and obtained all consents set forth on <u>Schedule 3.3</u> or will
              have done so prior to the Closing.&#160; <font style="color: rgb(0, 0, 0);">No &#8220;fair price,&#8221; &#8220;interested stockholder,&#8221; &#8220;business combination&#8221; or similar provision of any jurisdiction&#8217;s takeover or similar Law is, or at the Closing will be,
                applicable to the transactions contemplated by </font>this Agreement and the other documents contemplated hereby<font style="color: rgb(0, 0, 0);">.</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Financial Statements</u>.&#160; The Seller has delivered or made available to the Buyer its audited financial statements for the fiscal year ended December 31, 2021, and its
              unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of September 30, 2022 (the &#8220;<u>Seller Balance Sheet Date</u>&#8221;) and for the nine-month period then ended (collectively, the &#8220;<u>Seller
                Financial Statements</u>&#8221;).&#160; The Seller Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated.&#160; The Seller Financial Statements fairly present in all material respects
              the financial condition and operating results of the Seller as of the dates, and for the periods, indicated therein, except that the unaudited statements are subject to normal year-end adjustments and exclude the footnote disclosures and
              other presentation items required by GAAP.&#160; Except as set forth in the Seller Financial Statements, the Seller has no material liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of
              business subsequent to the Seller Balance Sheet Date; (ii) obligations under contracts and commitments incurred in the ordinary course of business; and (iii) liabilities and obligations of a type or nature not required under GAAP to be
              reflected in the Seller Financial Statements, which, in all such cases, individually and in the aggregate would not have a Material Adverse Effect on the Seller, the Business or the Purchased Assets.&#160; The Seller maintains and will continue to
              maintain a standard system of accounting established and administered in accordance with GAAP.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-4-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Adverse Changes</u>.&#160; Since the Seller Balance Sheet Date:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Seller has operated its business in the ordinary course and consistent with past practices.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Seller Party has (i) suffered a Material Adverse Effect or any effect, event or change that individually or in the aggregate could reasonably be expected to have a Material
              Adverse Effect; or (ii) become subject to any Liabilities related to the Business or otherwise Affecting the Purchased Assets;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Seller has:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent Affecting the Purchased Assets and except as required under this Agreement, used commercially reasonable efforts to preserve intact its present business
              organizations, lines of business, rights to retain its employees and its relationships with employees, customers, manufacturers, suppliers, vendors, distributors, contractors, licensors, licensees, lessors, Governmental Authorities and other
              Persons having business dealings with the Seller, in each case, consistent with the Seller&#8217;s past practice;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent Affecting the Purchased Assets, paid or performed in all material respects its obligations when due in the ordinary course of business consistent with past
              practice, including its obligations under each Contract;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (A) defended and protected the Product IP from infringement, (B) not taken, or omitted to take, any action that would reasonably be expected to render invalid or unenforceable
              any of the Product IP or affected adversely, limited, restricted, impaired or impeded the ability of the Seller (or, after the consummation of the transactions contemplated hereby, the ability of the Buyer) to use and practice the Product IP
              and (C) prosecuted and maintained all registrations and applications to register the Product IP, including paying any related fees when due, and not abandoned or otherwise allowed to lapse any of the foregoing; and</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; performed in all respects its respective obligations under each Contract Affecting the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Seller has not:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; sold, leased, licensed, transferred or disposed of or made any contract for the sale, lease, license, transfer or disposition of, or make subject to a security interest or any
              other Encumbrance, any of the Purchased Assets; merge or consolidate with any other Person or effect any business combination, recapitalization or similar transaction;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; amended or prematurely terminated, waived any material right or remedy under, or breach any obligation with respect to, any Contract Affecting the Purchased Assets;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; granted or incurred any Encumbrance on any of the Purchased Assets; or</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; commenced or settled any Proceeding Affecting the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-5-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Taxes</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no Encumbrances for Taxes on any of the Purchased Assets, other than Encumbrances for Taxes (i) not yet due and payable or (ii) which have been contested in good faith
              with the applicable taxing authority.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All Tax Returns required to be filed by or with respect to the Purchased Assets and/or the Seller have been timely filed, and all such Tax Returns are true, correct and complete
              in all material respects.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; All Taxes required to have been paid by any Seller Party (including with respect to the Purchased Assets) (whether or not shown on any Tax Return) have been paid on a timely basis.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Seller has waived or consented to extend the time in which any Tax Return may be filed that has not yet been filed or any Tax may be assessed or collected by any taxing
              authority, with respect to the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no action, suit, audit or other Proceeding now in progress, pending or threatened in writing or, to the knowledge of any Seller Party, orally against or with respect to
              the Purchased Assets in respect of Taxes.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Title to Purchased Assets</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Seller has good and marketable title to, is the sole legal, equitable and beneficial owner of, and has the unrestricted power and right to sell, assign and deliver the
              Purchased Assets.&#160; The Purchased Assets are free and clear of all Encumbrances of any kind or nature.&#160; Upon the Closing, the Buyer will acquire the exclusive legal, equitable and beneficial title or license to or a valid license interest in
              (as the case may be) the Purchased Assets, free and clear of all Encumbrances of any kind or nature.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No (i) Seller Party or Affiliate of the foregoing (other than the Seller) or (ii) any other Person has any right, title or interest in, to or under, or Encumbrance upon, any of
              the Purchased Assets, and the consummation of the transactions contemplated by this Agreement will not give any such Person (other than the Buyer), or result in any such Person (other than the Buyer) having, any right, title or interest in,
              or Encumbrance upon, any of the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No portion of the Business is conducted by any Seller Party or any Affiliate thereof (other than the Seller).</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Sufficiency and Condition of Assets</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchased Assets constitute all of the assets used in, necessary, or created as of [***] for the research, development, manufacture, marketing, packaging, commercialization,
              sale, offer for sale, use, import, export and regulatory approval of the Products to the extent such actions were conducted by the Seller immediately prior to [***].</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Seller and its Affiliates have not marketed, commercialized, distributed, or sold any of the Products at any time prior to the Closing Date and the Purchased Assets were
              suitable and adequate as of [***] for continued use in the manner then-conducted by the Seller as of immediately prior to [***].&#160; The inventory and samples, in each case as part of the Products, are of a quality and quantity usable in the
              ordinary course of business consistent with past practice, except in each case for excess, damaged, obsolete, or expired items.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-6-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.9&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<u>Litigation</u>.&#160; There is no Proceeding pending or, to the knowledge of the Seller, threatened against any Seller Party related to the Business or Affecting the Purchased
              Assets before any court, agency, authority or arbitration tribunal, that (a) would be reasonably expected to adversely impact the Business or Purchased Assets or (b) that challenges or seeks to prevent, enjoin or otherwise delay the
              transactions contemplated by this Agreement.&#160; No Seller Party has received any opinion or legal advice to the effect that any Seller Party is exposed from a legal standpoint to any Liability or disadvantage that may be material to the
              Business or the Purchased Assets.&#160; There are no actions or omissions of any Seller Party and to the knowledge of the Seller, no facts or events that could be reasonably expected to result in any Proceeding against any Seller Party related to
              the Business or Affecting the Purchased Assets or that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.&#160; No Seller Party has ever settled or compromised any suit, claim, action,
              arbitration, proceeding or investigation (whether filed or threatened) related to the Business or otherwise Affecting the Purchased Assets.&#160; There is no Proceeding by any Seller Party pending, or which any Seller Party has commenced
              preparations to initiate, against any other Person related to the Business or otherwise Affecting the Purchased Assets or that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.&#160; No
              Seller Party or any of its respective officers or other employees is subject to or in default with respect to any notice, order, writ, injunction or decree of any Governmental Authority or arbitration tribunal related to the Business or
              otherwise Affecting the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.10&#160;&#160;&#160;&#160;&#160;&#160;<u>Compliance with Laws</u>.&#160; Each Seller Party, and each of Seller&#8217;s direct and indirect owners, officers, directors, managers, and employees, and to the knowledge of the Seller,
              it agents and contractors, has complied in all material respects with, is not in material violation of, and have not received any written or oral notices of violation with respect to, any Laws applicable to any Seller Party related to the
              Business or otherwise Affecting the Purchased Assets, including but not limited to those that are applicable to the ownership, manufacture, research, development, investigational use, premarket approval, production, operation, storage,
              distribution, commercialization, pricing, sale, warehousing, packaging, labeling, advertising, promotion, record keeping, filing of reports, security, and handling and/or testing of the Purchased Assets and those to which Purchased Assets are
              subject, including those relating to occupational health and safety.&#160; Each Seller Party, and each of Seller&#8217;s direct and indirect owners, officers, directors, managers, and employees, and to the knowledge of the Seller, it agents and
              contractors has all material licenses, permits, approvals and qualifications from any Governmental Authority necessary to carry on the Business and all such items are in full force and effect, and each Seller Party, and each of Seller&#8217;s
              direct and indirect owners, officers, directors, managers, and employees, and to the knowledge of the Seller, it agents and contractors, is and has at all times been in material compliance with the terms thereof.&#160; No Seller Party, or direct
              or indirect owners, officers, directors, managers, employees, and to the knowledge of the Seller, it agents or contractors of Seller, has received any allegations from current or former employees, consultants or independent contractors with
              respect to any alleged act or omission arising under or relating to any noncompliance with any Law, and has not conducted or initiated any internal investigation or made a voluntary or involuntary disclosure to any Governmental Authority with
              respect to any alleged act or omission arising under or relating to any noncompliance with any Law, in each case related to the Business or otherwise Affecting the Purchased Assets.&#160; No Seller Party, or direct or indirect owners, officers,
              directors, managers, employees, and to the knowledge of the Seller, it agents or contractors of Seller, has received any notice or citation nor any written notice or communication from FDA or any other Governmental Authority for any actual or
              potential noncompliance with any of the foregoing in this <u>Section 3.10</u>, and, to the knowledge of the Seller, there exists no condition, situation or circumstance, nor has there existed such a condition, situation or circumstance,
              which, after notice or lapse of time, or both, would constitute noncompliance with or give rise to future Liability with regard to any of the foregoing in this <u>Section 3.10</u>.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-7-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.11&#160;&#160;&#160;&#160;&#160; <u>Environmental Matters</u>.&#160; Each Seller Party has conducted the Business at all times in compliance with all applicable Environmental Laws.&#160; To the knowledge of the Seller, no
              real property currently owned, leased or operated by any Seller Party and used in the Business in any manner contains, and, during the period of its ownership, operation or tenancy at any real property formerly owned, operated or leased by
              any Seller Party, no Hazardous Substance were released at such property Affecting the Purchased Assets, in each case, in amounts that would reasonably be expected to result in material liability to the Seller under any applicable
              Environmental Law.&#160; No Seller Party has received any request for information from any Governmental Authority pursuant to any Environmental Law or any notices, or demand letters from any Governmental Authority or other Person, which have not
              heretofore been resolved with such Governmental Authority or other Person, indicating that any Seller Party may be in violation of, or liable under, any Environmental Law Affecting the Purchased Assets.&#160; There are no Proceedings pending or,
              to the knowledge of the Seller, threatened against any Seller Party relating to any violation, or alleged violation, of any Environmental Law Affecting the Purchased Assets.&#160; No reports have been filed, or are required to be filed, by any
              Seller Party concerning the Release of any Hazardous Substance or the threatened or actual violation of any Environmental Law Affecting the Purchased Assets.&#160; No Seller Party has disposed of, released or transported in material violation of
              any applicable Environmental Law from any properties owned or operated, or formerly owned or operated, by any Seller Party used in the Business.&#160; To the knowledge of the Seller, no remediation or investigation of Hazardous Substances is
              occurring at any property owned or operated, or formerly owned or operated, by any Seller Party and used in the Business.&#160; No Seller Party has any material Liabilities relating to any Proceeding, settlement, court order, administrative order,
              regulatory requirement, judgment or claim asserted or arising under any Environmental Law or relating to a violation or alleged violation of any Environmental Law by any Seller Party or any Person Affecting the Purchased Assets.&#160; Each Seller
              Party has obtained and is in material compliance with all Environmental Permits (each of which is disclosed in <u>Schedule 3.11</u> of the Disclosure Schedule) necessary for the ownership, lease, operation or use of the Purchased Assets and
              all such Environmental Permits are in full force and effect and shall be maintained in full force and effect by any Seller Party through the Closing Date in accordance with Environmental Law, and the Seller is not aware of any condition,
              event or circumstance that might prevent or impede, after the Closing Date, the ownership, lease, operation or use of the Purchased Assets.&#160; The Seller has provided or otherwise made available to the Buyer and listed in <u>Schedule 3.11</u>
              of the Disclosure Schedule: any and all environmental reports, studies, audits, records, sampling data, site assessments, risk assessments, economic models and other similar documents with respect to Purchased Assets which are in the
              possession or control of any Seller Party related to compliance with Environmental Laws or the Release of Hazardous Materials.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.12&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Intellectual Property</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Schedule 3.12(a)</u> of the Disclosure Schedule contains a complete and accurate list of all Product IP that is the subject of an application, certificate, filing,
              registration or other document issued, filed with, or recorded by any Governmental Authority or similar entity, setting forth, for each item, the title, full legal name of the applicant(s) and owner(s) of record, applicable jurisdiction,
              status, application or registration number, and date of application, registration or issuance, as applicable (&#8220;<u>Registered Product IP</u>&#8221;).&#160; None of the Registered Product IP has been determined by any Governmental Authority to be invalid
              or unenforceable.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Seller Party has complied in all material respects with all the requirements of all applicable Patent, Trademark and copyright offices and all other applicable Governmental
              Authorities to maintain the Registered Product IP in full force and effect, including payment of all required fees when due to such offices or agencies.&#160; The Seller is listed in the records of the appropriate Governmental Authorities as the
              sole assignee and owner of each item of Registered Product IP.&#160; All assignments of Registered Product IP that are or may be required to be filed or recorded in order to be valid or effective against bona fide purchasers without notice of such
              assignment have been duly executed and filed or recorded with the applicable Patent, Trademark and copyright offices and all other applicable Governmental Authorities.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-8-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each item of Product IP is (i) solely owned by the Seller free and clear of any Encumbrances other than the Existing Licenses and (ii) transferable, assignable, and enforceable
              by the Seller at the Closing and will be transferable, assignable, and enforceable by the Buyer after the Closing.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as expressly set forth in the Existing Licenses, none of the Product IP is subject to any license, covenant, immunity, release, or other right of or for the benefit of any
              Person, or any agreement or obligation to grant or otherwise convey any such rights.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No claims (i) challenging the validity, enforceability, effectiveness or ownership of any of the Product IP or (ii) to the effect that the conduct of the Business, including the
              Products (or their manufacture, use or sale), infringes, misappropriates or violates or will infringe on, misappropriate or violate any Intellectual Property Rights of any Person have, in the five (5) years prior to the date hereof, been
              asserted in writing against any Seller Party or are threatened in writing by any Person.&#160; There are no interference, re-examination, reissue, opposition, nullity, inter partes review, covered business method review, post grant review, or
              cancellation proceedings pending that relate to any of the Product IP.&#160; The conduct of the Business, including the Products (or their manufacture, use or sale) do not infringe, misappropriate or violate any Intellectual Property Rights of any
              Person.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the Seller&#8217;s knowledge, no Person (including any current or former employee or consultant of any Seller Party) is (or immediately upon the Closing will be) infringing,
              violating or misappropriating the Product IP.&#160; In the five (5) years preceding the date hereof, no claim has been made by any Seller Party in writing against any Person alleging any infringement, violation or misappropriation of any Product
              IP.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Schedule 3.12(g)</u> of the Disclosure Schedule sets forth a complete and accurate listing of all licenses, sublicenses, covenants not to sue, and other agreements to which
              Seller is a party, or by which any Seller Party is bound or that any Product IP is subject to, and pursuant to which (i) any Seller Party is authorized or otherwise permitted to use any other Person&#8217;s Intellectual Property that is primarily
              used or held for use by any Seller Party in the Business, or necessary to conduct the Business (such agreements disclosed pursuant to this subclause (i), the &#8220;<u>Inbound IP Agreements</u>&#8221;), or (ii) any Person is authorized or otherwise
              permitted to use, or which conveys any license, covenant, immunity, release, or other right of or for the benefit of any Person with respect to, any Product IP (such agreements disclosed pursuant to this subclause (ii), the &#8220;<u>Existing
                Licenses</u>&#8221;).&#160; Prior to the date hereof, the Seller has provided to Buyer access to true, correct and complete copies of all Inbound IP Agreements and all Existing Licenses.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Seller Party has secured written assignments to the Seller of all right, title and interest in and to all Product IP from all current and former consultants, contractors,
              employees and other third parties (&#8220;<u>Creators</u>&#8221;) who contributed to the creation or development of Product IP and/or all Creators are subject to agreements which contain present assignment rights in the Product IP to the Seller (&#8220;<u>Assignments</u>&#8221;).&#160;







              Each Creator is listed on <u>Schedule 3.12(h)</u> of the Disclosure Schedule.&#160; No third party, including any former employer of any Creator, has any claim to any right, title or interest in, to or under any Product IP that is inconsistent
              with such Assignments.&#160; Each Creator and all other Persons to whom any Trade Secrets included in the Purchased Assets have been disclosed are subject to adequate and customary restrictions on the use and disclosure of such Trade Secrets, in
              each case with a duration that extends at least ten years past the Closing Date and, with respect to current and former employee Creators, to non-competition restrictions that extend at least one year from the last date such Creator is
              employed by the Seller, unless prohibited by applicable Law (&#8220;<u>Confidentiality Obligations</u>&#8221;).&#160; All such Assignments and Confidentiality Obligations are legal, valid and binding obligations, enforceable against the respective party in
              accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar Laws affecting the enforcement of creditors&#8217; rights in general and general
              principles of equity.&#160; No party to any such Assignment or agreements containing such Confidentiality Obligations (an &#8220;<u>NDA</u>&#8221;) is in violation or breach of any such Assignment or NDA including the Confidentiality Obligations.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-9-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Seller Party has taken reasonable measures consistent with industry practice to protect and preserve the confidentiality of all Trade Secrets included in or utilized in
              connection with the Product IP.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the execution, delivery or performance by the Seller of this Agreement or the other Transaction Agreements, nor the completion of the transactions contemplated hereby or
              thereby, will result in: (i) the breach, modification, cancellation, termination, or suspension of any Inbound IP Agreements or Existing Licenses; or (ii) the loss or impairment of ownership rights or any other rights to or under any Product
              IP; or the creation, vesting, extension, or expansion of any rights of any Person with respect to any Product IP.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of the Product IP was developed or created using any funding or facilities of a university, college, other educational institution or research center, or funding from any
              Governmental Authority, and none of the Product IP is subject to any rights of any Governmental Authority.</div>
            <div style="text-align: justify; text-indent: 72pt;"> <br>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.13&#160;&#160;&#160; <u>Restrictions on Business Activities</u>.&#160; There is no agreement or understanding (non&#8209;competition or otherwise, written or oral), commitment, judgment, injunction, order or decree
              to which any Seller Party is a party or otherwise binding upon any Seller Party that (a) prohibits, impairs or materially limits any Seller Party&#8217;s right to engage in the Business or otherwise own and use the Purchased Assets (or would
              prohibit, impair or materially limit the Buyer&#8217;s right to own and use the Purchased Assets as such rights exist immediately upon the Closing), or (b) imposes a &#8220;most favored nation&#8221; requirement or similar provision with respect to the
              Purchased Assets.&#160; Without limiting the generality of the foregoing, no Seller Party has (i) agreed to provide or make any rebate, penalty, change in pricing or other payment or other accommodation to any Person in the event that any Seller
              Party changes the terms applicable any Seller Party&#8217;s Services or (ii) entered into any Contract under which any Seller Party is restricted from selling, licensing, manufacturing, delivering or otherwise distributing or commercializing any of
              its Intellectual Property Rights or from providing Services to customers or potential customers or any class of customers, in any geographic area, during any period of time, or in any segment of the market.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.14&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Material Contracts</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Schedule 3.14</u> sets forth an accurate and complete list of each Contract that (i) the Seller has continuing obligations under, and/or (ii) is in effect as of the Closing
              Date, in each case, to which the Seller is a party that is related to the Business or otherwise Affecting the Purchased Asset, including, without limitation any of the following Contracts to the extent such Contracts are Affecting the
              Purchased Assets (each, a &#8220;<u>Material Contract</u>&#8221; and collectively, the &#8220;<u>Material Contracts</u>&#8221;):</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;each Contract containing (A) any covenant limiting the freedom of a Seller Party to engage in the Business, (B) any most-favored pricing arrangement or similar term by which any
              Person is or could become entitled to any benefit, right or privilege that must be at least as favorable to such Person as those offered to any other Person, (C) any exclusivity provision, right of first refusal or right of first negotiation
              or similar covenant, or (D) any non-solicitation provision;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; each Contract requiring payments to or from a Seller Party in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-10-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160; each Contract requiring payment by or to a Seller Party after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution
              agreement (identifying any that contain exclusivity provisions); (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of a Seller Party; (C) any dealer, distributor,
              joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which a Seller Party has continuing obligations to develop or market any product, technology or service, or any agreement pursuant
              to which a Seller Party has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by the applicable Seller Party; or (D) any Contract with any third party providing any services
              relating to the manufacture or production of any of the Products or any Contract to sell, distribute or commercialize any of the Products; and</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; each Contract containing any royalty, dividend or similar arrangement based on the revenue or profits of any Seller Party.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Seller has provided the Buyer with a true, correct and complete copy of each Material Contract, including all schedules, exhibits, annexes, appendixes, work orders, addendum
              or similar documents, and modifications, amendments and supplements thereto.&#160; No Seller Party has received any threat or notice of cancellation of any Material Contract by the other party thereto and, to the knowledge of the Seller, no
              Material Contract has been materially breached by the other party.&#160; There is no material breach or material default under any Material Contract either by any Seller Party or, to the knowledge of the Seller, by any other party thereto, no
              event has occurred that with the giving of notice, the lapse of time, or both would constitute a material breach or material default thereunder by the Seller or, to the knowledge of the Seller, any other party, and no Seller Party has
              received any claim of any such material breach or material default.&#160; Each of the Material Contracts constitutes the valid and legally binding obligation of the applicable Seller Party and, to the knowledge of the Seller, each other party
              thereto, enforceable in accordance with its terms (subject to any applicable bankruptcy, insolvency, reorganization, moratorium or similar Laws now or hereafter in effect relating to creditors&#8217; rights generally or to general principles of
              equity), and is in full force and effect.&#160; There are no oral Material Contracts.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the knowledge of the Seller, no Person is currently renegotiating, or has the contractual right to renegotiate, any amount paid or payable to any Seller Party under any
              Material Contract or any other term or provision of any Material Contract.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no Material Contracts containing &#8220;key man&#8221; or similar provisions requiring particular individuals to perform services on behalf of any Seller Party related to such
              Material Contracts.&#160; There are no understandings between any Seller Party and the counterparty in any of the Material Contracts regarding any specific individuals performing services on behalf of any Seller Party.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.15&#160;&#160;&#160;&#160;&#160;&#160; <u>Brokers</u>.&#160; No Person has been retained by or is authorized to act on behalf of any Seller Party who is entitled to any fee or commission as an investment banker, finder,
              broker or similar role in connection with the transactions contemplated by this Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.16&#160;&#160;&#160;&#160;&#160;&#160; <u>Solvency</u>.&#160; The Seller is not entering into this Agreement with the intent to hinder, delay or defraud any Person to which any Seller Party is, or may become, indebted.&#160; The
              purchase price and the Assumed Liabilities are not less than the reasonably equivalent value of the Purchased Assets.&#160; Each of the Seller&#8217;s assets, at a fair valuation, exceed their respective liabilities, and after the Closing and after
              giving effect to this Agreement and the other transactions contemplated hereby, the Seller will not be insolvent (either because its financial condition is such that the sum of its debts is greater than the fair value of its assets or because
              the present fair salable value of its assets will be less than the amount required to pay its probable liability on debts as they become absolute and matured).</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-11-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.17&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Regulatory Compliance</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160; All Purchased Assets which are subject to the jurisdiction of the FDA, were, and are, manufactured, researched, tested, developed, processed, labeled, packaged, stored, distributed,
              and marketed in compliance with all Laws, guidance or orders administered or issued by the FDA or any other Governmental Authority.&#160; All Purchased Assets manufactured or otherwise held by any Seller Party, are in compliance with applicable
              permits and notification requirements required by Laws for each site at which Purchased Assets are manufactured or held.&#160; No Seller Party, or direct or indirect owners, officers, directors, managers, employees, and to the knowledge of the
              Seller, it agents or contractors of Seller, is the subject, officially or otherwise, of any pending or, to the knowledge of the Seller, threatened investigation by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery,
              and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto.&#160; No Seller Party, or direct or indirect owners, officers, directors, managers, employees, and to the knowledge of the
              Seller, its agents or contractors of Seller, has committed any act, made any statement, or failed to make any statement that would provide a basis for the FDA to invoke its policy with respect to &#8220;Fraud, Untrue Statements of Material Facts,
              Bribery and Illegal Gratuities&#8221; and any amendments thereto.&#160; Each of Purchased Assets distributed, sold or leased, or service rendered, by any Seller Party or Seller&#8217;s direct and indirect owners, officers, directors, managers, and employees,
              and to the knowledge of the Seller, its agents and contractors complies with all applicable product safety standards of each applicable product safety agency, commission, board or other Governmental Authority.&#160; Each Seller Party and each of
              Seller&#8217;s direct and indirect owners, officers, directors, managers, and employees, and to the knowledge of the Seller, its agents and contractors is in compliance with all applicable FDA import and export requirements, including, but not
              limited to, import-for-export requirements, export notifications or authorizations and record keeping requirements.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160; During the three (3) years immediately prior to the Closing Date, no Purchased Assets has been recalled, suspended or discontinued in the United States or any other relevant
              jurisdiction due to a decision of any Seller Party.&#160; No Seller Party is aware of any fact or circumstance which would constitute a reasonable basis for any product recall, filed notification, field correction, safety alert or material
              complaint with respect to any Purchased Assets manufactured, sold or developed by any Seller Party or any third party on behalf of any Seller Party.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Seller Party, nor to the knowledge of the Seller, any current or former officer, employee, consultant, contractor or agent of any Seller Party, has made an untrue statement of
              a material fact or fraudulent statement to the FDA or other Governmental Authority performing similar functions or failed to disclose a material fact required to be disclosed to the FDA or such other Governmental Authority.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of any Seller Party or any officer, director, employee, contractor or agent of any Seller Party has been subject to, or convicted of any crime, or engaged in any conduct that
              would reasonably be expected to result in, debarment by 21 U.S.C. &#167; 335a(a) or authorized by 21 U.S.C. &#167; 335a(b) or any similar Law, exclusion, or suspension from participation in Medicare, Medicaid, TRICARE or any similar government health
              care program under Section 1128 of the Social Security Act of 1935, as amended, or any similar Laws or program, or otherwise under Section 306 of the Food, Drug and Cosmetic Act or any similar Law, and no action is pending or, to the
              knowledge of the Seller, is threatened, relating to such debarment or conviction of any Seller Party, or any such other Person.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-12-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; All clinical trials and research conducted or sponsored by any Seller Party: (i) have been conducted in compliance in all material respects with the required protocols, procedures
              and controls and Law including but not limited to Investigational New Drug (IND) guidelines, including those contained in 21 C.F.R. Part 312, Good Clinical Practice (GCP) guidelines, including those contained in 21 C.F.R. Parts 11, 50 and 56,
              Good Laboratory Practice (GLP) requirements and standards of 21 C.F.R. Part 58, and, in each case, any comparable state and other Laws; (ii) that are required to be registered on clinicaltrials.gov under 42 U.S.C. 282 and 42 C.F.R. Part 11
              have been properly and duly registered on clinicaltrials.gov, and clinical trial results information required to be submitted for such trials has been properly and duly submitted for posting on www.clinicaltrials.gov in conformance with the
              requirements of the Food, Drug, and Cosmetic Act, and related FDA policies, guidance, rules and regulations; (iii) the Seller has no knowledge of any available studies or trials the results of which reasonably call into question in any
              material respect the safety and effectiveness of the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Seller Party and, to the knowledge of the Seller, its directors, employees, contractors and agents (while acting in such capacity) are in material compliance with, and to
              the Seller&#8217;s knowledge, there are no facts or circumstances that would reasonably be expected to give rise to liability of any Seller Party under, any health care laws applicable to any Seller Party, or any of its products or activities,
              including, but not limited to: the Food, Drug and Cosmetic Act; Medicare (Title XVIII of the Social Security Act); Medicaid (Title XIX of the Social Security Act); the U.S. Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b))&#894; the federal
              physician self-referral (&#8220;Stark&#8221;) law (42 U.S.C. &#167; 1395nn)&#894; the Civil Monetary Penalty Law (42 U.S.C. &#167; 1320a-7a); any federal or state prohibition on the defrauding or making of or causing the defrauding of any third-party payer (including
              commercial and private payers, and Medicare Advantage plans) or any governmental authority that administers a federal or state health care program (including Medicare, Medicaid and state Medicaid Waiver Programs, and TRICARE), including the
              civil U.S. False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative U.S. False Claims Law (42 U.S.C. &#167; 1320a-7b(a)) and analogous state laws and regulations; the exclusion laws (42 U.S.C. Section 1320a-7); all regulations promulgated
              pursuant to such laws; and any other federal or state law or as the same may be amended, modified or supplemented from time to time, and any successor statute thereto that regulates the design, development, testing, studying, processing,
              storing, importing or exporting, licensing, labeling or packaging, advertising, distributing, selling, pricing, or marketing of drug products, or that is related to remuneration (including ownership) to or by physicians or other health care
              providers (including kickbacks) or the disclosure or reporting of the same, patient or program charges, record keeping, claims processing, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of
              services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care products or services.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.18&#160;&#160;&#160;&#160;&#160; <u>Data Protection</u>.&#160; Each Seller Party has complied with all Laws and their respective published privacy policies and internal privacy policies and guidelines relating to
              privacy, data protection and data security, including with respect to the collection, storage, transmission, transfer (including cross-border transfers), disclosure and use of personally identifiable information (including personally
              identifiable information of employees, contractors, and third parties who have provided information to the Seller).&#160; Each Seller Party has taken commercially reasonable administrative, technical and physical measures to ensure that personally
              identifiable information is protected against loss, damage, and unauthorized access, use, modification, or other misuse.&#160; There has been no loss, damage, or unauthorized access, use, modification, or other misuse of any personally
              identifiable information maintained by or on behalf of any Seller Party; no Person (including any Governmental Authority) has made any claim or commenced any Proceeding with respect to loss, damage, or unauthorized access, use, modification,
              or other misuse of any such information; and there is no reasonable basis for any such claim or action.&#160; The execution, delivery and performance of this Agreement and the other Transaction Agreements and the consummation of the transactions
              contemplated hereby and thereby comply (and the disclosure to and use by the Buyer of such information after the Closing Date will comply) with each Seller Party&#8217;s applicable privacy policies and with all Laws relating to privacy and data
              security.&#160; Each Seller Party has at all times made all disclosures to, and obtained any necessary consents from, users, customers, employees, contractors, and other applicable Persons required by Laws related to privacy and data security and
              have filed any required registrations with the applicable data protection authority.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-13-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div>
              <div style="text-align: justify; text-indent: 36pt;">3.19&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance With Anti-Corruption Laws</u>.</div>
              <div><br>
              </div>
            </div>
            <div>
              <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the past five (5) years, none of any Seller Party or any of their directors, officers, or, to the knowledge of the Seller, any employees or agents of any Seller Party, has
                directly or indirectly, taken any action that would cause them to be in violation of (i)<font style="color: rgb(255, 0, 0);">&#160;</font>(i) the principles set out in the Organization for Economic Cooperation and Development Convention on
                Combating Bribery of Foreign Public Officials in International Business Transactions; (ii) the Foreign Corrupt Practices Act of 1977, as amended, or any rules or regulations thereunder, or (iii) any other applicable anti-corruption and/or
                anti-bribery Laws of any jurisdiction applicable to the Seller (whether by virtue of jurisdiction or organization or conduct of business) (collectively, the &#8220;<u>Applicable Anti-Corruption Laws</u>&#8221;).</div>
              <div>&#160;</div>
              <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the past five (5) years, none of any Seller Party or any of their directors, officers, or, to the knowledge of the Seller, any employees or agents of any Seller Party, has,
                in connection with the Business, directly or indirectly, offered, paid, promised to pay, or authorized a payment, of any money or other thing of value (including any fee, gift, sample, travel expense or entertainment) or any commission
                payment, or any payment related to political activity, to any of the following persons for the purpose of influencing any act or decision of such person in his or her official capacity, inducing such person to do or omit to do any act in
                violation of the lawful duty of such official, securing any improper advantage, or inducing such person to use his or her influence with a foreign government or instrumentality thereof to affect or to influence any act or decision of such
                government or instrumentality, in order to assist any Seller Party in obtaining or retaining business for or with, or directing the business to, any Person:&#160; (i) any person who is an agent, representative, official, officer, director, or
                employee of any non-U.S. government or any department, agency, or instrumentality thereof (including officers, directors, and employees of state-owned, operated or controlled entities) or of a public international organization; (ii) any
                person acting in an official capacity for or on behalf of any such government, department, agency, instrumentality, or public international organization; (iii) any political party or official thereof; (iv) any candidate for political or
                political party office (such recipients in paragraphs (i), (ii), (iii) and (iv) of this subsection collectively, &#8220;<u>Government Officials</u>&#8221;); or (v) any other individual or entity while knowing or having reason to believe that all or any
                portion of such money or thing of value would be offered, given, or promised, directly or indirectly, to any Government Official.</div>
              <div>&#160;</div>
              <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Seller Party has devised and, for the past five (5) years, maintained a system of internal accounting controls sufficient to provide reasonable assurance that:&#160; (i)
                transactions are executed and access to assets is permitted only in accordance with such Seller Party&#8217;s applicable policies and procedures and management&#8217;s general or specific authorization, and (ii) transactions have been recorded as
                necessary to permit preparation of periodic financial statements and to maintain accountability for assets, and the Seller has otherwise established internal controls and procedures intended to ensure compliance with Applicable
                Anti-Corruption Laws.</div>
              <div>&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The books, records and accounts of each Seller Party have, for the past five (5) years, accurately and fairly reflected, in reasonable detail, the transactions and dispositions of
              their respective funds and assets with respect to the Business in all material respects.&#160; In the past five (5) years, there have not been any false or fictitious entries made in the books, records or accounts of any Seller Party with respect
              to the Business relating to any illegal payment or secret or unrecorded fund, and the Seller has not established or maintained a secret or unrecorded fund.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the past five (5) years, no Seller Party or any of their directors, officers, or, to the knowledge of the Seller, employees or agents of any Seller Party, has made any
              payments or transfers of value with the intent, or that have the purpose or effect, of engaging in commercial bribery, or acceptance of or acquiescence in kickbacks or other unlawful or improper means of obtaining business.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-14-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the past five (5) years, no Seller Party has entered into any transaction with any of its Affiliates that has provided to such Seller Party revenues, earnings or assets that
              would not have been available to it in an arm&#8217;s length transaction with an unaffiliated Person.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; For purposes of this Section only, the term &#8220;agents&#8221; shall also mean, with respect to any Person, such Person&#8217;s resellers, distributors, consultants and intermediaries.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.20&#160;&#160;&#160;&#160;&#160;&#160; <u>Trade Law Compliance</u>.&#160; In the past five (5) years, each Seller Party has operated the Business in accordance with all applicable Trade Laws.&#160; Without limiting the
              foregoing:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; during the past five (5) years, each Seller Party has, as may be relevant with respect to the Business, obtained and is in compliance with, all required export licenses, license
              exceptions and other export authorizations (&#8220;<u>Export Approvals</u>&#8221;), if any;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;there are no pending or threatened claims pertaining to the Business with respect to such Export Approvals or Trade Laws,</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the knowledge of the Seller, there are no actions, conditions or circumstances pertaining to the Business that may give rise to any future claims under any Trade Laws;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no Export Approvals are required with respect to the transactions contemplated hereby;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;none of any Seller Party or any directors or officers of any Seller Party, or to the knowledge of the Seller, any employees or agents of any Seller Party is a Restricted Party;</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;during the past five (5) years, none of any Seller Party or, to the knowledge of Seller, any Seller Party&#8217;s Representatives or any other party has, with respect to the Business,
              made any voluntary disclosures to, or has been subject to any fines, penalties or sanctions from, any Governmental Authority regarding any violations of Trade Laws; and</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Schedule 3.20(g)</u> of the Disclosure Schedule sets forth the Export Control Classification Number(s) of the Purchased Assets, and the basis for such classification.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.21&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Suppliers</u>.&#160; <u>Schedule 3.21</u> of the Disclosure Schedule sets forth a complete and correct list of all manufacturers, suppliers, and vendors of the Products and any
              other Persons involved in the Business.&#160; Since the Seller Balance Sheet Date, no Seller Party has received any notice, letter, complaint or other communication from any of the foregoing to the effect that it has changed, modified, amended or
              reduced, or is reasonably likely to change, modify, amend or reduce, its business relationship with any Seller Party with respect to the Products or Business in a manner that is, or is reasonably likely to be, adverse to any Seller Party or,
              following the Closing, to the Buyer.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.22&#160;&#160;&#160;&#160;&#160;&#160; <u>No Other Agreements</u>.&#160; No Seller Party or any Representatives any Seller Party has entered into any other agreement or arrangement with respect to the sale or other
              disposition of the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">3.23&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Additional Representations</u>.&#160; The Seller acknowledges that none of the Buyer, any Affiliate of the Buyer, or any other Person acting on behalf of the Buyer or an
              Affiliate of the Buyer, has made any representation or warranty, express or implied, regarding the Buyer or its Affiliates, except as expressly set forth in this Agreement and any certificate delivered pursuant hereto.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-15-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">3.24&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Representations Complete</u>.&#160; To the knowledge of the Seller, none of the representations or warranties of the Seller in this Agreement or any statement made in any Schedule
              or certificate furnished by the Seller as of the Closing pursuant to this Agreement contains any untrue statement of a material fact, or omits to state any material fact necessary in order to make the statements contained herein or therein,
              in the light of the circumstances under which made, not misleading.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">ARTICLE IV</div>
            <div style="text-align: center; font-weight: bold;">REPRESENTATIONS AND WARRANTIES OF THE BUYER</div>
            <div>&#160;</div>
            <div>The Buyer represents and warrants to the Seller as of the date of this Agreement and as of Closing Date as follows:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Organization</u>.&#160; The Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware <font style="color: rgb(0, 0, 0);">and


                has the requisite </font>corporate <font style="color: rgb(0, 0, 0);">power and authority to own, lease and operate all of its properties and assets and to carry on its business as it is now being conducted and as currently proposed to be
                conducted</font>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">4.2&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority for Agreement</u>.&#160; The Buyer has full corporate power and authority to enter into and perform its obligations under this Agreement and the other documents
              contemplated hereby to which the Buyer is or will be a party and to consummate the transactions contemplated hereby and thereby.&#160; The shareholders and <font style="color: rgb(0, 0, 0);">the board of directors </font>of the Buyer have duly
              authorized the execution, delivery and performance of this Agreement and the other documents contemplated hereby and the consummation of the transactions contemplated hereby and thereby.&#160; No other corporate action on the part of the Buyer or
              any shareholder, director or other equityholder or governing body of Buyer is necessary to approve and authorize the execution, delivery and performance of this Agreement and the other documents contemplated hereby and the consummation of the
              transactions contemplated hereby and thereby.&#160; This Agreement and the other documents contemplated hereby have been duly executed and delivered by the Buyer and assuming the due execution and delivery by the Seller hereto and thereto, are
              legal, valid and binding obligations of the Buyer, enforceable against the respective party in accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or
              other similar Laws affecting the enforcement of creditors&#8217; rights in general and general principles of equity.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">4.3&#160;&#160;&#160;&#160;&#160;&#160; <u>No Violation to Result</u>.&#160; The execution, delivery and performance by the Buyer of this Agreement and the other documents contemplated hereby and the consummation by the Buyer
              of the transactions contemplated hereby and thereby, do not and will not:&#160; (a) violate, breach or constitute a default under (i) any of the terms of the organizational documents of the Buyer, or any resolution adopted by any of the
              shareholders or directors of the Buyer, (ii) any material contract to which the Buyer or by which it or its assets are bound or (iii) any Law applicable to the Buyer or (b) give any Governmental Authority the right to prohibit any of the
              transactions contemplated by this Agreement, except in the cases of (a)(ii), (a)(iii) and (b) as would not reasonably be expected to prevent consummation of the transactions contemplated by this Agreement.&#160; No notice to, filing with, or
              consent of, any Person is necessary for or in connection with the authorization, approval, execution, delivery or performance by the Buyer of this Agreement and the other documents contemplated hereby or the consummation by the Buyer of the
              transactions contemplated hereby or thereby, except where the failure to obtain such consent or to make such filing or provide notification would not, individually or in the aggregate, (A) prevent or materially delay the consummation of the
              transactions contemplated by this Agreement or (B) reasonably be expected to result in a Material Adverse Effect on the Buyer.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-16-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Brokers</u>.&#160; Except for RM Global Partners, no Person has been retained by or is authorized to act on behalf of the Buyer who is entitled to any fee or commission as an
              investment banker, finder, broker or similar role in connection with the transactions contemplated by this Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Litigation</u>.&#160; There is no Proceeding pending or, to the knowledge of the Buyer, threatened against or affecting the Buyer before any court, agency, authority or arbitration
              tribunal or that would be reasonably expected to prevent or materially delay the consummation of the transactions contemplated by this Agreement.&#160; To the knowledge of the Buyer, there are no actions or omissions of the Buyer and no facts or
              events that could be reasonably expected to result in any such Proceeding against the Buyer.&#160; There is no Proceeding by the Buyer pending, or which the Buyer has commenced preparations to initiate, against any other Person that would be
              reasonably expected to prevent or materially delay the consummation of the transactions contemplated by this Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Availability of Funds</u>.&#160; The Buyer has, or will have, sufficient cash on hand or other sources of immediately available funds to pay the Closing Payment and if applicable,
              the Holdback Amount when due pursuant to this Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Additional Representations</u>.&#160; The Buyer acknowledges that none of the Seller, any Affiliate of the Seller, or any other Person acting on behalf of the Seller or an
              Affiliate of the Seller, has made any representation or warranty, express or implied, regarding the Seller or its Affiliates, except as expressly set forth in this Agreement and any certificate delivered pursuant hereto.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">ARTICLE V</div>
            <div style="text-align: center; font-weight: bold;">ADDITIONAL AGREEMENTS</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Access to Properties and Records</u>.&#160; After the Closing Date, the Seller shall, and shall cause each other Seller Party to, provide the Buyer and its Representatives with
              access, subject to applicable Law, at reasonable times, on reasonable notice and during ordinary business hours, at the Seller&#8217;s place of business, to such information related to the Business or otherwise Affecting the Purchased Assets in any
              Seller Party&#8217;s possession or control as is reasonably necessary for financial reporting, contract administration, audit, regulatory compliance and accounting matters, the preparation and filing of any Tax Returns, reports or forms, or the
              defense of any Tax claim or assessment, and the Buyer and its Representatives shall be permitted to make extracts from, or take copies of, any books, records or other documentation related to the Business or otherwise Affecting the Purchased
              Assets as may be reasonably necessary for any such purposes.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Publicity and Disclosure</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Buyer and the Seller shall mutually determine the initial press release announcing this Agreement and the transactions contemplated hereby prior to its release.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Party shall make any disclosure of this Agreement or the existence, terms and conditions hereof (whether or not in response to an inquiry about the existence or subject matter
              of this Agreement), other than to its Representatives in connection with the transactions contemplated by this Agreement, unless previously approved by the other Party; <u>provided</u>, <u>however</u>, that the Buyer acknowledges and agrees
              that (i) the Seller shall make any and all disclosures as may be required by the US Securities and Exchange Commission, the Nasdaq Stock Market, LLC, and any other applicable Laws (including the filing of this Agreement), and (ii) nothing
              contained herein shall prohibit any Seller Party from making any disclosure which such Seller Party in good faith believes is required by, or advisable according to, applicable Laws, in each case, so long as the Seller has provided reasonable
              notice to the Buyer and considered all timely comments from Buyer in good faith.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-17-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;That certain Confidentiality Agreement, dated as of October 7, 2022, by and between the Seller and the Buyer (the &#8220;<u>CDA</u>&#8221;) applies to all Confidential Information disclosed
              by the Parties in connection with this Agreement. The Parties agree that, upon the Closing (i) Purchased Assets will constitute Confidential Information of Buyer and Buyer shall be deemed the &#8220;disclosing party&#8221; and Seller the &#8220;receiving
              party&#8221; with respect thereto for all purposes of the CDA, and (ii) the Purchased Assets are not considered to have been in the possession of Seller or independently developed by Seller for purposes of Section 5 of the CDA.&#160; In the event of a
              conflict between this Agreement and the CDA, the terms and provisions of this Agreement shall control.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Tax Matters</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding any provision herein to the contrary, (i) all Taxes other than income, sales and use, value added, and withholding Taxes levied with respect to the Purchased Assets
              for a taxable period that includes (but does not end on) the Closing Date (the &#8220;<u>Straddle Period</u>&#8221;) shall be apportioned between the Seller, on the one hand, and the Buyer, on the other hand, based on the relative number of days included
              in such period through and including the Closing Date and the number of days included in such period after the Closing Date, respectively and (ii) all income, sales and use, value added, and withholding Taxes levied with respect to the
              Purchased Assets for a Straddle Period shall be apportioned between the Seller, on the one hand, and the Buyer, on the other hand, as determined from the books and records of the Seller with respect to the Business as if the taxable year of
              the Business terminated as of the close of business on the Closing Date.&#160; To the extent that any portion of such a pro-rated Tax is paid or required by Law to be paid by one Party hereto but required by the foregoing to be borne by another
              Party hereto, such other Party shall promptly pay or reimburse the Tax-paying Party for the proper portion of the Tax required to be so borne upon notice from the Tax-paying Party of the amount of such Tax required to be paid or reimbursed.&#160;
              Each Party shall timely and duly cause to be filed all Tax Returns and other documentation with respect to all Taxes subject to this <u>Section 5.3(a)</u> that are required by Law to be filed by such Party, and shall pay to the relevant
              Governmental Authority all such Taxes that are required to be paid by such Party (subject to such reimbursement as provided for herein).</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160; Notwithstanding any provision herein to the contrary, all Transfer Taxes incurred in connection with the transactions contemplated by this Agreement shall be borne fifty percent
              (50%) by the Seller and fifty percent (50%) by the Buyer.&#160; Such Transfer Taxes shall be paid by the party obligated to pay such Transfer Taxes pursuant to applicable law when due, and the Seller shall file all necessary Tax Returns and other
              documentation with respect to all such Transfer Taxes.&#160; The costs and expenses incurred in connection with the preparation of such Tax Returns shall be borne fifty percent (50%) by the Seller and fifty percent (50%) by the Buyer, and the
              Buyer promptly shall reimburse the Seller for its share of such costs and expenses paid by the Seller upon the request of Seller.&#160; If required by applicable Law, the Buyer shall, and shall cause its Affiliates to, join in the execution of any
              such Tax Returns and other documentation, and the Buyer shall cooperate with the Seller in connection with such Tax Returns.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">5.4&#160;&#160;&#160;&#160;&#160;&#160; <u>Bulk Transfer Provisions</u>.&#160; Each Party hereto hereby waives compliance with the provisions of any applicable bulk transfer Law; provided, however, that the Seller agrees (a)
              to pay and discharge when due or to contest or litigate all claims of creditors that are asserted against the Buyer or the Purchased Assets by reason of noncompliance with any such Law, (b) to indemnify, defend and hold harmless the Buyer
              from and against any and all such claims in the manner provided in <u>ARTICLE VI</u> and (c) to take promptly all necessary action to remove any Encumbrance on the Purchased Assets by reason of such noncompliance.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-18-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">5.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Purchased Assets</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that, at any time or from time to time following the Closing, any Party identifies any asset that is included within the definition of Purchased Assets but such
              asset was not transferred as of Closing (including as a result of any Seller Party or any other Person having any right, title or interest in, to or under, or Encumbrance upon, any of the Purchased Assets), then the Seller shall, and shall
              cause each Seller Party, other Person and its and their respective Representatives to (a) promptly transfer, or cause to be transferred, such asset to the Buyer for no additional consideration, and (b) execute and deliver to the Buyer such
              other instruments of sale, transfer, conveyance, assignment, license, and confirmation, provide such materials and information and take such other actions as the Buyer may reasonably deem necessary or desirable in order to effectively
              transfer, convey and assign to the Buyer, and to confirm the Buyer&#8217;s title to, all of the Purchased Assets, free and clear of all Encumbrances, in accordance with the terms of this Agreement and the other Transaction Agreements, and, to the
              fullest extent permitted by Law, to put the Buyer in actual possession and operating control of the Purchased Assets, to reasonably assist the Buyer in exercising all rights with respect thereto, and otherwise to cause the Seller to fulfill
              its obligations under this Agreement and the other Transaction Agreements.&#160; In the event that any such asset is transferred under this <u>Section 5.5</u>, then such transferred asset automatically shall be deemed a &#8220;Purchased Asset&#8221; for all
              purposes under this Agreement including the indemnification obligations under <u>ARTICLE VI </u>and the limitations thereto.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent that the right and ability to enforce any confidentiality or use restrictions relating to any Product IP (including, without limitation, any Confidentiality
              Obligations) are not validly transferred to the Buyer pursuant to this Agreement or the other Transaction Agreements, the Seller (i) hereby authorizes the Buyer and its designees to enforce such restrictions to protect its rights and
              interests, including any Trade Secrets, with respect to such Product IP, (ii) if requested by the Buyer or its designee, will enforce such restrictions as directed by the Buyer or its designee, at the Buyer&#8217;s cost and expense, and (iii)
              agrees to provide such cooperation, assistance and information in connection with any such enforcement as reasonably requested by the Buyer or its designee, including causing any other Seller Party to take the actions set forth in this <u>Section

                5.5(b)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the period beginning on the Closing Date and ending on [***], each Seller Party shall (i) reasonably cooperate with the Buyer to enforce the Product IP and to contest or
              defend against any Proceeding relating to the transactions contemplated by this Agreement or the other Transaction Agreements, (ii) reasonably cooperate with the Buyer in its efforts to continue and maintain for the benefit of the Buyer those
              business relationships of any Seller Party existing prior to the Closing and relating to the business to be operated by the Buyer after the Closing that is primarily related to the Products, (iii) satisfy the Excluded Liabilities in a manner
              that is not detrimental to any such relationships, and (iv) refer to the Buyer all inquiries primarily related to the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the period beginning on the Closing Date and ending on [***], prior to or at the time entering into any agreement or arrangement with respect to, or effecting, any merger,
              statutory exchange or other business combination or proposed sale or exchange, dividend or other distribution or liquidation of all or a significant portion of the Seller&#8217;s assets or equity in one or a series of transactions or any
              significant recapitalization or reclassification of its outstanding securities that could impair the Seller&#8217;s ability to meet its current and future obligations hereunder, the Seller shall use reasonable best efforts to provide for the
              assumption of all of the obligations of Seller set forth herein.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-19-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as expressly authorized by the Buyer, the Seller agrees that, from and after the Closing Date, the Seller shall not, and shall cause each Seller Party, other Person and
              its and their respective Representatives not to, retain disclose or use any copy of any of the Product IP included in the Purchased Assets and information contained therein.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">&#160;[***]&#160;&#160;&#160;&#160; <u>[***]</u>.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">ARTICLE VI</div>
            <div style="text-align: center; font-weight: bold;">SURVIVAL AND INDEMNIFICATION</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Survival of Representations, Warranties and Covenants</u>.&#160; All (i) representations and warranties contained in this Agreement and any certificate delivered pursuant hereto
              shall survive the Closing for a period from the Closing Date to the twenty-four (24) month anniversary of the Closing Date (the &#8220;<u>Expiration Date</u>&#8221;)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>and
              shall thereafter expire, and (ii) claims based on intentional misconduct, fraud or criminal conduct shall survive indefinitely.&#160; Except as provided herein, no claim for indemnification for a breach of a representation or warranty may be made
              under this <u>ARTICLE VI</u> after the Expiration Date.&#160; Notwithstanding the foregoing, any representation or warranty or covenant or agreement with respect to which a claim has been duly made under this <u>ARTICLE</u> VI for breach thereof
              prior to the end of the applicable survival period pursuant to this <u>Section 6.1</u> shall survive until such claim is resolved.&#160; All covenants, agreements, or obligations in this Agreement that by their terms apply or are to be performed
              in whole or in part after the Closing Date shall survive until performed in accordance with their terms.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Indemnification by the Seller</u>.&#160; Subject to <u>Section 6.3</u>, the Seller covenants and agrees to indemnify, defend, protect and hold harmless each of the Buyer
              Indemnified Parties from, against and in respect of all Damages suffered, sustained, incurred or paid by any Buyer Indemnified Party, in each case in connection with, resulting from or arising out of (whether or not involving a Third Party
              Claim):</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any inaccuracy in or the breach of any representation or warranty made by the Seller set forth in this Agreement or in any certificate delivered pursuant hereto (&#8220;<u>Seller Rep
                Breaches</u>&#8221;);</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160; any breach or non-fulfillment of any covenant, agreement, or obligation on the part of any Seller Party set forth in this Agreement or in any certificate delivered pursuant hereto;
              and</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any Excluded Asset or Excluded Liability, including, without limitation, (i) any claims related to or arising out of any breach, default or violation of any Assumed Contracts by
              any Seller Party on or prior to the Closing or otherwise related to the activities of any Seller Party on or prior to the Closing in connection with the Assumed Contracts, (ii) any Third-Party Claim arising out of or related to the business
              or assets of a Seller Party or any action or inaction of a Seller Party on or prior to the Closing, and (iii) any enforcement of indemnification rights of any Buyer Indemnified Party under this <u>Article VI</u> including the recovery of
              Damages due to any Buyer Indemnified Party under this <u>Article VI</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitations on Indemnification of Seller</u>.&#160; The aggregate indemnification obligations of the Seller under this Agreement shall not exceed the Holdback Amount; provided that
              the foregoing limitation shall not apply to (i) claims under <u>Sections 6.2(b)-(c)</u>, which shall be limited to an amount equal to the sum of (A) the Closing Payment, <u>plus</u> (B) the amount of the Holdback Amount, or (ii) claims
              based on intentional misconduct, criminal conduct or fraud, for which the indemnification obligations hereunder shall be unlimited.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-20-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>General Provisions and Limitations</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any claim for indemnification under this <u>ARTICLE VI</u> may include claims for potential or contingent Damages where the full amount of Damages is not then readily
              determinable.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the sole purpose of determining the amount of any Damages with respect to any breach of any representation, warranty or covenant by either Party for purposes of
              indemnification under this <u>ARTICLE VI</u> (and not for determining whether or not any breaches of representations, warranties or covenants have occurred), any qualification or limitation of a representation, warranty or covenant by
              reference to materiality of matters stated therein or as to matters having or not having &#8220;Material Adverse Effect,&#8221; &#8220;materiality&#8221; or words of similar effect, shall be disregarded.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding anything herein to the contrary, no Party shall be entitled to reimbursement under any provision of this Agreement for any amount to the extent such Party has
              previously been reimbursed for such amount under any other provision of this Agreement or any claim, recovery, settlement, or payment by or against any other Person.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;From and after the delivery of a notice of a claim for indemnification under this <u>ARTICLE VI</u>, the Buyer and the Seller shall reasonably cooperate with and grant the other
              Party and their respective Representatives reasonable access, during normal business hours, to the books, records, personnel and properties of such Party to the extent reasonably related to such claim.&#160; Notwithstanding the foregoing, no Party
              shall have any obligation under this <u>Section 6.4(d)</u> to make available any information if making such information available would (i) jeopardize any attorney-client privilege, or (ii) contravene any applicable Law, fiduciary duty or
              binding agreement (including any confidentiality agreement to which such Party is a party) (it being understood that each Party shall cooperate in any reasonable efforts and requests for waivers that would enable otherwise required disclosure
              to occur without contravening such Law, duty or agreement).</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms and conditions set forth herein, the Buyer&#8217;s decision to discontinue or delay the development or commercialization of the Products for any reason post-Closing
              shall not impact the Seller&#8217;s right to the Holdback Amount or the Buyer&#8217;s obligation to make such payment pursuant to <u>Section 6.7</u> and the Buyer shall not have a claim for indemnification or Damages pursuant to this Agreement solely
              due to such discontinuation or delay.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Indemnification Procedures</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that, subsequent to the Closing, any Buyer Indemnified Party (the &#8220;<u>Indemnified Party</u>&#8221;) receives notice of the assertion of any claim or demand or the
              commencement of any Proceeding against such Indemnified Party by any Person who is not a party to this Agreement (a &#8220;<u>Third Party Claim</u>&#8221;), and for which such Indemnified Party may be entitled to indemnification pursuant to this <u>ARTICLE

                VI</u>, the Indemnified Party shall promptly give written notice thereof, together with a statement of any available information regarding such Third Party Claim, to the Seller (the &#8220;<u>Indemnifying Party</u>&#8221;); provided, however, that any
              failure on the part of the Indemnified Party to so notify the Indemnifying Party shall not limit any of the obligations of the Indemnifying Party or any of the rights of the Indemnified Party under this <u>ARTICLE VI</u> (except to the
              extent such failure materially prejudices the defense of such claim, demand or Proceeding).&#160; The Indemnified Party shall have the right, in its sole discretion and at its election by written notice to the Indemnifying Party (the &#8220;<u>Defense
                Notice</u>&#8221;) within fifteen (15) days after delivering notice of the Third Party Claim to the Indemnifying Party, to conduct the defense against such claim in its own name.&#160; If the Indemnified Party fails to timely give the Defense Notice,
              it will be deemed to have elected not to conduct the defense of the subject claim, and in such event the Indemnifying Party shall have the right, at its own cost and expense, to conduct the defense in good faith with counsel reasonably
              satisfactory to the Indemnified Party; provided, however, that the Party conducting such defense: (x) shall keep the other Party reasonably informed regarding the status of such claim, (y) shall provide the other Party with the reasonable
              opportunity to consult with the such Party regarding the defense of such claim, and (z) may not settle or compromise any such claim, demand or Proceeding without the prior written consent of the other Party (which consent shall not be
              unreasonably withheld, conditioned or delayed).</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-21-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that any Indemnified Party desires to seek indemnification under this <u>ARTICLE VI</u>, the Indemnified Party shall give prompt written notice to the Indemnifying
              Party, which written notice shall include a general summary of the basis for such claim and the amount, to the extent known, of the claim; provided, however, any failure on the part of the Indemnified Party to so notify the Indemnifying Party
              shall not limit any of the obligations of the Indemnifying Party, or any of the rights of any Indemnified Party, under this <u>ARTICLE VI</u> (except to the extent such failure materially prejudices the Indemnifying Party).&#160; Upon receipt of
              the written notice from the Indemnified Party of a claim, the Indemnifying Party shall have thirty (30) days in which to investigate the claim.&#160; If the Indemnifying Party disputes the claim for indemnification or any portion thereof, the
              Indemnifying Party shall notify the Indemnified Party in writing (which notification shall set forth in reasonable detail the grounds for such objection) within such thirty (30) day period, whereupon the Indemnified Party and the Indemnifying
              Party shall promptly meet and attempt in good faith to resolve their differences with respect to such claim or any portion of such claim for indemnification.&#160; If the dispute has not been resolved within thirty (30)&#160;days after the Indemnifying
              Party&#8217;s notice of such dispute, either the Indemnifying Party or the Indemnified Party may proceed with pursuing the remedies provided herein to resolve such dispute.&#160; In the event no written notice disputing or objecting to such claim or any
              portion of such claim for indemnification is delivered by the Indemnifying Party prior to the expiration of the thirty (30) days in which the Indemnifying Party may dispute such claim for indemnification, the claim(s) stated by the
              Indemnified Party shall be conclusively deemed to be approved by and be an obligation of the Indemnifying Party (a &#8220;<u>Waived Claim</u>&#8221;).</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">6.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Payable and Unresolved Claims</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A &#8220;<u>Payable Claim</u>&#8221; shall mean an Indemnified Party&#8217;s claim for indemnification of Damages under this <u>ARTICLE VI</u>, to the extent that such claim has not yet been
              fully satisfied by payment to the Indemnified Party, that is (i) resolved by a final and non-appealable judgment (a &#8220;<u>Resolved Claim</u>&#8221;), (ii) covered by an agreement between the applicable Indemnified Party and Indemnifying Party to
              resolve such dispute as evidenced by a memorandum setting forth such agreement signed by all applicable parties (a &#8220;<u>Settled Claim</u>&#8221;) or (iii) a Waived Claim.&#160; An &#8220;<u>Unresolved Claim</u>&#8221; shall mean any Indemnified Party&#8217;s then-pending
              claim for indemnification of Damages under this <u>ARTICLE VI</u> to the extent that such claim is not a Payable Claim and has not been fully satisfied by payment to the Indemnified Party.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">On the date any claim becomes a Payable Claim, the Indemnifying Party shall cause the amount of such Payable Claim to be paid to the applicable
              </font>Indemnified Party <font style="color: rgb(0, 0, 0);">in accordance with this <u>Section 6.6(b)</u></font>.&#160; The Indemnified Parties shall be entitled to recover all Payable Claims directly from the Indemnifying Party, subject to the
              limitations on the Indemnifying Party&#8217;s indemnification obligations set forth in <u>Section 6.3</u>.&#160; <font style="color: rgb(0, 0, 0);">Any such amount payable pursuant to the foregoing clause (ii) shall be paid promptly (but in no event
                later than five (5) Business Days after the applicable payment obligation accrues) by the Indemnifying Party by wire transfer in immediately available funds to such account or accounts as may be designated in writing by the Indemnified
                Party.</font></div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-22-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">6.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Release of Holdback Amount</u>.&#160; Promptly following the Expiration Date, the Buyer will pay to the Seller by wire transfer of immediately available funds to the Seller
              Account, the remainder of the Holdback Amount, less any amounts required to satisfy any then pending claims (&#8220;<u>Pending Claims</u>,&#8221; and the amounts required to satisfy any such Pending Claims, the &#8220;<u>Set Aside Amounts</u>&#8221;).&#160; Upon the
              final determination of any such Pending Claims or the mutual agreement of the Buyer and the Seller, the Buyer will be entitled to retain the amount awarded to the Buyer in such final determination or such amount as mutually agreed to by the
              Buyer and the Seller (the &#8220;<u>Indemnified Amount</u>&#8221;) with respect to such Pending Claim, if any, and, within five (5) Business Days of the final determination of such Pending Claim, the Buyer will pay to the Seller an amount, if any, equal
              to (a) the Set Aside Amount with respect to such Pending Claim, <u>minus</u> (b) the Indemnified Amount with respect to such Pending Claim to the Seller Account.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">6.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exclusive Remedy</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The remedies provided for in this Agreement shall be the sole and exclusive remedies of the Parties and their respective officers, directors, employees, Affiliates, agents,
              Representatives, successors and assigns for any breach of or inaccuracy in any representation or warranty contained in this Agreement or any certificate delivered pursuant hereto; provided, that, the foregoing does not (a) waive or affect any
              claims for fraud, breaches of covenants, or relating to criminal investigations or Proceedings, or relieve or limit the Liability of any Party or other Person from any Liability arising out of or resulting from fraud or criminal
              investigations or Proceedings in connection with the transactions contemplated by this Agreement or any certificate delivered pursuant hereto or (b) waive or affect any equitable remedies to which a Party may be entitled.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In furtherance of the foregoing, and for the avoidance of doubt, the Holdback Amount shall be (i) the sole and exclusive source of recovery for Damages for the Buyer Indemnified
              Parties under this Agreement for claims for indemnification under <u>Section 6.2(a)</u>, and (ii) exhausted in its entirety or unavailable before a Buyer Indemnified Party may seek to recover Damages under <u>Sections 6.2(b) - (c)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No exercise of, or failure to exercise, the rights set forth in this <u>ARTICLE VI</u> shall constitute an election of remedies or limit such Indemnified Party&#8217;s other rights
              hereunder or otherwise.&#160; Such remedy shall be in addition to and not in limitation of any injunctive relief or other rights or remedies to which any Indemnified Party is or may be entitled at law or in equity or under this Agreement or any
              other Transaction Agreement (including any exhibits hereto).</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">ARTICLE VII</div>
            <div style="text-align: center; font-weight: bold;">COVENANT NOT TO COMPETE</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Non-Competition; Non-Solicitation</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the period commencing with the Closing and ending on [***], no Seller Party, its controlled Affiliates and their respective successors and assigns (it being understood for
              the avoidance of doubt, that the officers of the Seller as of the Closing Date shall not be considered Affiliates of any Seller Party solely for purposes of this <u>Article VII</u> and as a result, not subject to the restrictive covenants in
              this <u>Article VII</u>) shall, for any reason whatsoever, directly or indirectly, as a principal or for its own or another&#8217;s account, on behalf of or in conjunction with any other Person or through any form of ownership in any Person,
              anywhere in the world:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">[***]&#160;&#160;&#160;&#160; [***];</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-23-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 108pt;"><font style="color: #000000;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">intentionally disrupt or interfere with, or attempt to disrupt or interfere with, the relations of the
                Buyer or any of its Affiliates with any actual employee, contractor, manufacturer, supplier, vendor, service provider, licensor, licensee, customer or strategic partner of the Business as of the Closing Date with respect to the </font>Products

              <font style="color: rgb(0, 0, 0);">(the &#8220;<u>Covered Persons</u>&#8221;) or cause any such Person to terminate its relationship with the Buyer or its Affiliates or advise any Person against entering into such relationship; or</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">disparage or make any false or inaccurate statements (whether in oral, written, electronic or other form) to any media source, industry
                member-company or group, financial institution or Covered Person regarding the Buyer or its Affiliates or the Purchased Assets</font>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties intend that this <u>ARTICLE VII</u> be in compliance with California Business and Professions Code Section 16601, to the extent applicable, and further intend for it
              to be fully enforceable.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Damages</u>.&#160; Because of the difficulty of measuring economic losses to the Buyer and its Affiliates as a result of a breach of the foregoing covenants in this <u>ARTICLE VII</u>,
              and because of the immediate and irreparable damage that could be caused to the Buyer and its Affiliates for which it would have no other adequate remedy, the Seller hereby agrees that the foregoing covenants contained in this <u>ARTICLE VII</u>
              may be enforced by the Buyer in the event of a breach or threatened breach by any of the Seller, in addition to, but not in lieu of, any other available remedies (including monetary Damages), by injunctions, restraining orders or other
              equitable remedies, without necessity of posting an injunction bond.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">7.3&#160;&#160;&#160;&#160;&#160;&#160; <u>Reasonable Restraint</u>.&#160; It is agreed by the Parties that the foregoing covenants in this <u>ARTICLE VII</u> are necessary to protect the legitimate interests of the Buyer
              and impose a reasonable and valid restraint on each Seller Party in light of the activities and business of the Seller Parties, the Buyer and the Buyer&#8217;s Affiliates on the date of the execution of this Agreement and the current plans of the
              Seller Parties, the Buyer and its Affiliates.&#160; The Seller agrees that the foregoing covenants in this <u>ARTICLE VII</u> do not unreasonably restrict any Seller Party&#8217;s ability to operate its business after the Closing.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Independent Covenant</u>.&#160; It is understood by the Parties that each of the covenants contained in this <u>ARTICLE VII</u> are essential elements of this Agreement and that,
              but for the agreement of the Seller to comply with such covenants, the Buyer would not have agreed to enter into this Agreement.&#160; The Seller hereby agrees that all covenants contained in this <u>ARTICLE VII</u> are material, reasonable and
              valid and waives all defenses to the strict enforcement hereof by the Buyer.&#160; The covenants in this <u>ARTICLE VII</u> are severable and separate, and the unenforceability of any specific covenant shall not affect the provisions of any other
              covenant and the existence of any claim or cause of action of the Seller against the Buyer, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Buyer of any such covenant.&#160; Moreover, in
              the event that any court of competent jurisdiction shall determine that the scope, time or territorial restrictions set forth are not permitted by applicable Law or are too broad or to any extent invalid, then it is the intention of the
              Parties that such restrictions be enforced to the fullest extent which the court deems to be permissible by applicable Law, and this Agreement shall thereby be reformed subject to the Buyer&#8217;s right to appeal the court&#8217;s initial determination
              of excessive breadth or other invalidity.&#160; The covenants contained in this <u>ARTICLE VII</u> shall have no effect if the transactions contemplated by this Agreement are not consummated.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-24-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: center; font-weight: bold;">ARTICLE VIII</div>
            <div style="text-align: center; font-weight: bold;">MISCELLANEOUS</div>
            <div>&#160;</div>
            <div>
              <div style="text-align: justify; text-indent: 36pt;">8.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Successors and Assigns</u>.&#160; This Agreement shall inure to the benefit of and be binding upon the Seller, the Buyer and their respective successors and permitted assigns;
                provided, however, that no Party shall make any assignment of this Agreement or any interest herein without the prior written consent of the other Party, and any such purported assignment without such prior written consent shall be void and
                of no force or effect; provided, however, that the Buyer may assign all or any of its respective rights and obligations hereunder (a) to any of its Affiliates or, after the Closing, in connection with a merger, consolidation or sale of all
                or substantially all of the assets of the Buyer or any of its Subsidiaries, or (b) as collateral security to any lender to the Buyer or an Affiliate of the Buyer.&#160; Any such assignment will not relieve the party making the assignment from
                any liability under this Agreement.&#160; Subject to the preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns, and any reference to a Party
                shall also be a reference to the successors and permitted assigns thereof.</div>
              <div>&#160;</div>
              <div><br>
              </div>
            </div>
            <div>
              <div style="text-align: justify; text-indent: 36pt;">8.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Governing Law; Dispute Resolution</u>.</div>
              <div><br>
              </div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH
              STATE.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event of any Proceeding between the Parties arising out of or relating to this Agreement or the transactions contemplated hereby, whether in contract, tort, equity or
              otherwise, and whether relating to the meaning, interpretation, effect, validity, performance or enforcement of this Agreement or the transactions contemplated hereby and thereby, such Proceeding shall be resolved by and through an
              arbitration proceeding to be conducted under the auspices and the Commercial Arbitration Rules of the American Arbitration Association (or any like organization successor thereto) in the State of Delaware.&#160; The arbitrability of the dispute,
              claim or controversy shall likewise be determined in the arbitration.&#160; Both the foregoing agreement of the parties to arbitrate any and all such disputes, claims and controversies, and the results, determinations, findings, judgments and/or
              awards rendered through any such arbitration shall be final and binding on the Parties and may be specifically enforced by legal proceedings in any court of competent jurisdiction.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the avoidance of doubt, the arbitrator(s) shall follow any applicable federal law and Delaware state law (with respect to all matters of substantive law) in rendering an
              award.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The cost of the arbitration Proceeding and any Proceeding in court to confirm or to vacate any arbitration award, as applicable (including each Party&#8217;s reasonable attorneys&#8217; fees
              and costs), shall be borne by the unsuccessful party.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Specific Performance; Remedies</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party acknowledges that the other Parties shall be irreparably harmed and that there shall be no adequate remedy at law for any violation by any of them of any of the
              covenants or agreements contained in this Agreement.&#160; It is accordingly agreed that, in addition to, but not in lieu of, any other remedies that may be available upon the breach of any such covenants or agreements (and notwithstanding <u>Section

                8.2</u> hereof), each Party shall have the right to obtain injunctive relief to restrain a breach or threatened breach of, or otherwise to obtain specific performance of, the other Party&#8217;s covenants and agreements contained in this
              Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise provided herein, all rights and remedies of the Parties under this Agreement shall be cumulative, and the exercise of one or more rights or remedies shall not
              preclude the exercise of any other right or remedy available under this Agreement or applicable Law.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-25-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">8.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Severability</u>.&#160; Each section, subsection and lesser section of this Agreement constitutes a separate and distinct undertaking, covenant and/or provision hereof.&#160; In the
              event that any provision of this Agreement shall finally be determined to be unlawful, such provision shall be deemed severed from this Agreement, but every other provision of this Agreement shall remain in full force and effect; provided,
              however, that upon such determination that any term or other provision is unlawful, the Parties hereto shall modify this Agreement so as to effect the original intent of the Parties as closely as possible in a legally valid manner in order
              that each transaction contemplated hereby is consummated as originally contemplated to the greatest extent possible.&#160; The preceding sentence is in addition to and not in place of the severability provisions in <u>ARTICLE VII</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Amendment</u>.&#160; This Agreement may be amended, supplemented or modified only by execution of a written instrument signed by the Buyer and the Seller.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Waiver</u>.&#160; Either the Buyer (with respect to the Buyer), on the one hand, or the Seller (with respect to the Seller), on the other hand, may to the extent permitted by
              applicable Law (a) extend the time for the performance of any of the obligations or other acts of the other Party, (b) waive any inaccuracies in the representations and warranties of the other Party contained herein or in any document
              delivered pursuant hereto or (c) waive compliance with any of the agreements, covenants or obligations of the other Party contained herein.&#160; No such extension or waiver shall be effective unless set forth in a written instrument duly executed
              by or on behalf of the Party extending the time of performance or waiving any such inaccuracy or non-compliance.&#160; No waiver by any Party of any term of this Agreement, in any one or more instances, shall be deemed to be or construed as a
              waiver of the same or any other term of this Agreement on any future occasion.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.7&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notices</u>.&#160; All notices, requests, consents, waivers and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been
              duly given (a) if personally delivered, upon delivery or refusal of delivery, (b) if mailed by registered or certified United States mail, return receipt requested, postage prepaid, upon delivery or refusal of delivery, (c) if sent by a
              nationally recognized overnight delivery service, upon delivery or refusal of delivery or (d) if sent by email transmission, on the day on which such email transmission was sent.&#160; All notices, consents, waivers or other communications
              required or permitted to be given hereunder shall be addressed as follows:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to the Buyer:</div>
            <div>&#160;</div>
            <div style="text-indent: 130.5pt;">GC Biopharma Corp.</div>
            <div style="text-indent: 130.5pt;">107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do</div>
            <div style="text-indent: 130.5pt;">16924, Republic of Korea</div>
            <div style="text-indent: 130.5pt;">Attention: [***]</div>
            <div style="text-indent: 130.5pt;">E-mail: [***]</div>
            <div><br>
            </div>
            <div style="text-indent: 130.3pt;">with a copy to:</div>
            <div><br>
            </div>
            <div style="margin-left: 130.5pt;">DLA Piper LLP (US)</div>
            <div style="margin-left: 130.5pt;">One Liberty Place</div>
            <div style="margin-left: 130.5pt;">1650 Market Street, Suite 5000</div>
            <div style="margin-left: 130.5pt;">Philadelphia, PA 19103-7300</div>
            <div style="margin-left: 130.5pt;">Attention: [***]</div>
            <div style="text-indent: 130.3pt;">E-mail: [***]</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-26-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div><br>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to the Seller:</div>
            <div>&#160;</div>
            <div style="margin-left: 130.5pt;">Catalyst Biosciences, Inc.</div>
            <div style="margin-left: 130.5pt;">611 Gateway Blvd., Suite 120</div>
            <div style="margin-left: 130.5pt;">San Francisco, CA 94080</div>
            <div style="margin-left: 130.5pt;">Attention: [***]</div>
            <div style="margin-left: 130.5pt;">E-mail: [***]</div>
            <div><br>
            </div>
            <div style="text-indent: 130.3pt;">with a copy to:</div>
            <div><br>
            </div>
            <div style="margin-left: 130.5pt;">Orrick, Herrington &amp; Sutcliffe LLP</div>
            <div style="margin-left: 130.5pt;">51 West 52nd Street</div>
            <div style="margin-left: 130.5pt;">New York, NY 10019</div>
            <div style="margin-left: 130.5pt;">Attention:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***] and [***]</div>
            <div style="margin-left: 130.5pt;">E-mail: [***] and [***]</div>
            <div><br>
            </div>
            <div>&#160;</div>
            <div>or at such other address or addresses as the Party addressed may from time to time designate in writing pursuant to notice given in accordance with this <u>Section 8.7</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.8&#160;&#160;&#160;&#160;&#160;&#160; <u>Expenses</u>.&#160; Except to the extent such costs and expenses represent Damages indemnifiable by an Indemnifying Party pursuant to <u>ARTICLE VI</u> or are addressed in <u>Section

                5.3</u>, all costs and expenses of the Seller (including financial advisory fees, legal fees and expenses, broker and finder fees, and fees and expenses of accountants) incurred by the Seller in connection with the transactions contemplated
              hereby shall be borne by the Seller, and all costs and expenses of the Buyer (including financial advisory fees, legal fees and expenses, broker and finder fees, and fees and expenses of accountants) incurred by the Buyer in connection with
              the transactions contemplated hereby shall be borne by the Buyer.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Complete Agreement</u>.&#160; This Agreement, those documents expressly referred to herein, including all appendices, exhibits and schedules hereto, and the other documents of even
              date herewith, embody the complete agreement and understanding among the Parties and supersede and preempt any prior understandings, agreements or representations by or among the Parties, written or oral, which may have related to the subject
              matter hereof.&#160; Notwithstanding the right of the Buyer to investigate the assets, properties, books, records and financial condition of the Seller, and notwithstanding any knowledge obtained or obtainable by the Buyer as a result of such
              investigation, the Buyer has the unqualified right to rely upon, and has relied upon, each of the representations and warranties made by the Seller in this Agreement or pursuant hereto.&#160; The waiver of any condition based on the accuracy of
              any representation or warranty, or on the performance of or compliance with any covenant or obligation, shall not adversely affect the right to indemnification, payment of Damages or any other remedy based on such representations, warranties,
              covenants or obligations.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.10&#160;&#160;&#160;&#160;&#160; <u>Absence of Third Party Beneficiary Rights</u>.&#160; Except for <u>ARTICLE VI</u> (which shall be for the benefit of the Indemnified Parties), no provision of this Agreement is
              intended, or will be interpreted, to provide or create any third party beneficiary rights or any other rights of any kind in any client, customer, Affiliate, shareholder, employee or partner of any Party hereto or any other Person.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.11&#160;&#160;&#160;&#160;&#160; <u>Mutual Drafting</u>.&#160; This Agreement is the mutual product of the Parties, and each provision hereof has been subject to the mutual consultation, negotiation and agreement of
              each of the Parties, and shall not be construed for or against any Party hereto, but according to the application of the rules of interpretation of contracts.&#160; Each Party <font style="color: rgb(0, 0, 0);">waives the application of any Law
                or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document.</font></div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-27-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;">8.12&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Further Representations</u>.&#160; Each Party acknowledges and represents that it has been represented by its own legal counsel in connection with the transactions contemplated by
              this Agreement, with the opportunity to seek advice as to its legal rights from such counsel.&#160; Each Party further represents that it is being independently advised as to the Tax or securities consequences of the transactions contemplated by
              this Agreement and is not relying on any representations or statements made by any other Party as to such Tax and securities consequences.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.13&#160;&#160;&#160;&#160;&#160;&#160; <u>Interpretation</u>.&#160; Unless the context clearly indicates otherwise, where appropriate the singular shall include the plural and the masculine shall include the feminine or
              neuter, and vice versa, to the extent necessary to give the terms defined herein and/or the terms otherwise used in this Agreement the proper meanings.&#160; Unless otherwise stated, &#8220;including&#8221; and &#8220;e.g.&#8221; are not exclusive or limiting (and will
              be deemed followed by &#8220;without limitation&#8221;).</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.14&#160;&#160;&#160;&#160; <u>Headings</u>.&#160;&#160;&#160;&#160;&#160; The headings in this Agreement are intended solely for convenience of reference and shall be given no effect in the construction or interpretation of this
              Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.15&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>.&#160; This Agreement may be executed in two or more counterparts, each of which when executed and delivered shall be deemed an original and all of which, taken
              together, shall constitute one and the same agreement.&#160; This Agreement and any document or schedule required hereby may be executed and delivered by facsimile or electronic mail of a &#8220;.pdf&#8221; data file, which shall be considered legally binding
              for all purposes.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 36pt;">8.16&#160;&#160;&#160;&#160;&#160; <u>Conflict Waiver</u>.&#160; Each of Cooley LLP and Dentons US LLP (the &#8220;<u>Seller IP Law Firms</u>&#8221;) has acted as counsel to the Seller and its Affiliates (individually and
              collectively, the &#8220;<u>Seller Group</u>&#8221;) in connection with the Product IP.&#160; Seller shall not seek or have the Seller IP Law Firms disqualified from any representation of the Buyer or its Affiliates based upon the prior representation of the
              Seller Group.&#160; Each of the parties hereto hereby consents to the representation of the Buyer and its Affiliates by the Seller IP Law Firms in connection with the Product IP and waives any conflict of interest arising from such representation,
              and each of such parties shall cause any of its Affiliates to consent to waive any conflict of interest arising from such representation.&#160; Each of the parties acknowledges that such consent and waiver is voluntary, that it has been carefully
              considered, and that the parties have consulted with counsel or have been advised they should do so in connection herewith.&#160; This Section 8.16 shall not be deemed exclusive of any other rights to which the Seller IP Law Firms is entitled
              whether pursuant to law, contract or otherwise.</div>
            <div>&#160;</div>
            <div style="text-align: center; text-indent: 36pt;">[<font style="font-style: italic;">Balance of page intentionally left blank.&#160; Signatures appear on following pages.</font>]</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-28-</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, each Party hereto has signed or has caused to be signed by its officer thereunto duly authorized this Asset Purchase Agreement as
              of the date first above written.</div>
            <div><br>
            </div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zb12d9f04f1ba4b499171e7c3f1293e55">

                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="vertical-align: top;">
                    <div style="font-weight: bold;">BUYER:</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td style="width: 5%; vertical-align: top;">&#160;</td>
                  <td style="width: 45%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="vertical-align: top;">
                    <div style="font-variant: small-caps; font-weight: bold;">GC BIOPHARMA CORP.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td style="width: 5%; vertical-align: top;">&#160;</td>
                  <td style="width: 45%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                    <div>By:</div>
                  </td>
                  <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                    <div>Name:</div>
                  </td>
                  <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div>Eun Chul Huh</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                    <div>Title:</div>
                  </td>
                  <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div>President &amp; CEO</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td style="width: 5%; vertical-align: top;">&#160;</td>
                  <td style="width: 45%; vertical-align: top;">&#160;</td>
                </tr>

            </table>
            <div><br>
            </div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zd7d2c777b4d0466a9858044f36b67af0">

                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="vertical-align: top;">
                    <div style="font-weight: bold;">SELLER:</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td colspan="2" style="vertical-align: top;">
                    <div style="font-variant: small-caps; font-weight: bold;">CATALYST BIOSCIENCES, INC.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top;">&#160;</td>
                  <td style="width: 5%; vertical-align: top;">&#160;</td>
                  <td style="width: 45%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                    <div>By:</div>
                  </td>
                  <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                    <div>Name:</div>
                  </td>
                  <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
                  </td>
                </tr>
                <tr>
                  <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                    <div>Title:</div>
                  </td>
                  <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
                  </td>
                </tr>

            </table>
            <div><br>
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: center; font-variant: small-caps; font-weight: bold;"><font style="color: rgb(0, 0, 0); text-transform: uppercase;">Appendix</font> A</div>
            <div style="text-align: center; font-variant: small-caps; font-weight: bold;"> <br>
            </div>
            <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;"><u>Defined Terms</u></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Affecting the Purchased Assets</u>&#8221; means in any manner, in whole or in part, primarily relating to, impacting, used in, necessary for or otherwise directly or indirectly
              affecting the Purchased Assets.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Affiliate</u>&#8221; means, as to any Party, any Person which, directly or indirectly, is in control of, is controlled by, or is under common control with, such Party.&#160; For purposes
              of this definition, an entity shall be deemed to be &#8220;controlled by&#8221; a Person if the Person possesses, directly or indirectly, power either to (a) vote twenty five percent (25%) or more of the securities (including convertible securities) of
              such entity having ordinary voting power or (b) direct or cause the direction of the management or policies of such entity whether by contract or otherwise; and, as to a Party who is a natural Person, such Person&#8217;s spouse, parents, siblings
              and lineal descendants.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Agreement</u>&#8221; has the meaning given to such term in the <u>Preamble</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Applicable Anti-Corruption Laws</u>&#8221; has the meaning given to such term in <u>Section 3.19(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Assigned Patents</u>&#8221; means (a) the Patents listed in <u>Schedule 3.12(a)</u> of the Disclosure Schedule and any and all Patents arising therefrom, (b) all other Patents
              owned by Seller or its Affiliates that are necessary for the development, manufacture, commercialization, sale, use or regulatory approval of the Products.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Assigned Trademarks</u>&#8221; means the Trademarks listed in <u>Schedule 3.12(a)</u> of the Disclosure Schedule.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Assignments</u>&#8221; has the meaning given to such term in <u>Section 3.12(h)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Assumed Contracts</u>&#8221; means the (a) Contracts set forth on <u>Schedule 1.1</u>, and (b) any other Contract (i) related to the Product and/or the Product IP, (ii) that Buyer
              notified Seller in writing that it desires to assume within the [***] month period after the Closing Date, and (iii) that is not terminated at such time Buyer provides notification pursuant to the preceding clause (b)(ii), in each case,
              including any right to receive the benefit of all obligations thereunder, and the right to receive payment or goods and services thereunder, and to assert claims and take other rightful actions in respect of breaches, defaults and violations
              thereunder, in each case, for which notice or consent is obtained from the counterparty to such Contract if required under the applicable Contract.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<u>Assumed Liabilities</u>&#8221; has the meaning given to such term in <u>Section 1.4</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(10)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Bill of Sale, Assignment and Assumption Agreement</u>&#8221; means the agreement substantially in the form set forth in <u>Exhibit A</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(11)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Business</u>&#8221; means [***].</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(12)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Business Day</u>&#8221; means any day other than a Saturday, a Sunday or a day on which commercial banks in San Francisco, California, New York, New York, and Seoul, Korea are closed.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(13)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Buyer</u>&#8221; has the meaning given to such term in the <u>Preamble</u>.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(14)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Buyer Indemnified Party</u>&#8221; means the Buyer, its Affiliates, and their respective Representatives, successors and assigns, and the officers, directors, employees,
              stockholders and members thereof.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(15)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>CDA</u>&#8221; has the meaning given to such term in <u>Section 5.2(c)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(16)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Closing</u>&#8221; means the closing of the transactions contemplated by this Agreement.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(17)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Closing Date</u>&#8221; means the date on which the Closing occurs.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(18)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Closing Payment</u>&#8221; has the meaning given to such term in <u>Section 2.3(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(19)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(20)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Confidential Information</u>&#8221; has the meaning given to such term in the CDA.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(21)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Confidentiality Obligations</u>&#8221; has the meaning given to such term in <u>Section 3.12(h)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(22)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Contract</u>&#8221; means any note, bond, mortgage, debt instrument, security agreement, contract, license, lease, sublease, covenant, commitment, power of attorney, proxy,
              indenture, purchase and sale order, or other agreement or arrangement, oral or written, to which any Seller Party is currently a party or by which any Seller Party or any of its assets or property are currently bound, including any and all
              amendments, waivers or other changes thereto.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(23)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Creators</u>&#8221; has the meaning given to such term in <u>Section 3.12(h)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(24)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Damages</u>&#8221; means all Liabilities, losses, claims, damages, causes of actions, lawsuits, administrative Proceedings (including informal Proceedings), investigations, audits,
              demands, assessments, adjustments, judgments, settlement payments, deficiencies, penalties, fines, Taxes, and costs and expenses (including reasonable and documented attorneys&#8217; fees); provided, however, that &#8220;Damages&#8221; shall not include any <font style="color: rgb(0, 0, 0);">punitive, incidental, consequential, special or indirect damages (except to the extent reasonably foreseeable as of the Closing)</font>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(25)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Defense Notice</u>&#8221; has the meaning given to such term in <u>Section 6.5(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(26)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Disclosure Schedule</u>&#8221; has the meaning given to such term in <u>ARTICLE III</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(27)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Encumbrance</u>&#8221; means any claim, lien, pledge, assignment, option, charge, easement, license, restraint, security interest, right-of-way, encumbrance, mortgage or other right
              or obligation (including with respect to Intellectual Property Rights, any license, covenant, authorization, non-assert, release or immunity), other than encumbrances created by or through the Buyer.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(28)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Environmental Laws</u>&#8221; means all Laws, ordinances, regulations, codes, orders, judgments, injunctions, awards or decrees relating to pollution, protection of the environment,
              public or worker health and safety as they relate to exposure to Hazardous Substances, or the emission, discharge, release or threatened release of pollutants, contaminants or industrial, medical, toxic or hazardous substances or wastes into
              the environment or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of pollutants, contaminants or industrial, medical, toxic or hazardous substances or wastes,
              including the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section 9601 et seq., the Resource Conservation and Recovery Act, 42 U.S.C. Section 6901 et seq., the Toxic Substances Control Act, 15 U.S.C.
              Section 2601 et seq., the Federal Water Pollution Control Act, 33 U.S.C. Section 1251 et seq., the Clean Air Act, 42 U.S.C. Section 7401 et seq., the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. Section 111 et seq., the
              Occupational Safety and Health Act, 29 U.S.C. Section 651 et seq., the Asbestos Hazard Emergency Response Act, 15 U.S.C. Section 2643 et seq., the Safe Drinking Water Act, 42 U.S.C. Section 300f et seq., the Oil Pollution Act of 1990 and
              analogous state acts, and all such Laws, ordinances, regulations, codes, orders, judgments, injunctions, awards and decrees as are applicable.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(29)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Environmental Permit</u>&#8221; means any permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required under or issued, granted, given,
              authorized by or made pursuant to Environmental Law.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(30)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Excluded Assets</u>&#8221; has the meaning given to such term in <u>Section 1.2</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(31)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Excluded Liabilities</u>&#8221; means (a) any Liability of any Seller Party of any kind, known or unknown, contingent or otherwise, not specifically enumerated as an Assumed
              Liability (including Taxes for which Seller is responsible under <u>Section 5.3</u>), and (b) all Taxes relating to the Purchased Assets or the Assumed Liabilities arising from or relating to a period ending on or before the Closing Date.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">[***]&#160;&#160;&#160;&#160; [***]</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(33)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Existing Licenses</u>&#8221; has the meaning given to such term in <u>Section 3.12(g)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(34)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Export Approvals</u>&#8221; has the meaning given to such term in <u>Section 3.20(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(35)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>FDA</u>&#8221; means the United States Food and Drug Administration.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(36)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>GAAP</u>&#8221; means United States generally accepted accounting principles, consistently applied.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(37)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Governmental Authority</u>&#8221; means any federal, state or local or foreign government, any political subdivision thereof or any court, administrative or regulatory agency,
              department, instrumentality, ministry, body or commission or other governmental or other public authority or agency, domestic or foreign.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(38)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Government Officials</u>&#8221; has the meaning given to such term in <u>Section 3.19(b)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(39)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Hazardous Substance</u>&#8221; means any toxic waste, pollutant, hazardous substance, toxic substance, hazardous waste, special waste, industrial substance or waste, petroleum or
              petroleum-derived substance or waste, radioactive substance or waste, or any constituent of any such substance or waste, or any other substance regulated under or defined by any Environmental Law.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(40)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Holdback Amount</u>&#8221; means $5,000,000.00.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(41)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Inbound IP Agreements</u>&#8221; has the meaning given to such term in <u>Section 3.12(g)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(42)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Indemnified Party</u>&#8221; has the meaning given to such term in <u>Section 6.5(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(43)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Indemnifying Party</u>&#8221; has the meaning given to such term in <u>Section 6.5(a)</u>.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(44)&#160;&#160;&#160;&#160; &#8220;<u>Intellectual Property</u>&#8221; means all embodiments of Intellectual Property Rights, including without limitation, whether in electronic, written or other media, including diagrams,
              inventions (whether or not patentable), invention disclosures, know-how, methods, network configurations and architectures, proprietary information, protocols, schematics, design information, bills of material, specifications, technical data,
              software (in any form, including source code and executable or object code), build scripts, test scripts, algorithms, APIs, subroutines, techniques, user interfaces, URLs, web site content, works of authorship, documentation (including
              instruction manuals, samples, studies, and summaries), databases and data collections.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(45)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Intellectual Property Rights</u>&#8221; means any or all of the following: (a) all United States, international and foreign patents, utility models, industrial rights and
              applications therefor, and all reissues, reexaminations, divisions, divisionals, renewals, extensions, provisionals, continuations and continuations-in-part thereof, and all patents, applications, registrations and filings claiming priority
              to or serving as a basis for priority thereof (collectively, &#8220;<u>Patents</u>&#8221;); (b) all Trade Secret rights and other rights with respect to Know-How and other technical information, whether or not Patented or the subject of an application
              for Patent and whether or not Patentable; (c) all copyrights and other rights of authorship, under any statute, common law or other law of any country, or under any treaty or international agreement or convention, together with all grants,
              registrations and applications relating thereto, in all original works of authorship fixed in a tangible medium of expression, and other rights in works of authorship (including computer software, documentation, designs, and graphic works),
              whether or not registered or the subject of an application for registration and whether or not registrable; (d) all rights with respect to industrial designs and all variants of industrial designs, whether or not registered or the subject of
              an application for registration and whether or not registrable; and (e) all rights with respect to trademarks, design marks, logos, service marks, certification marks, official marks, trade names, business names, corporate names, trade dress,
              and other characters, brand elements or other distinguishing features used in connection with goods or services, whether or not registered or the subject of an application for registration and whether or not registrable, and all related
              goodwill (collectively, &#8220;<u>Trademarks</u>&#8221;); (f) all rights with respect to Web addresses, websites and domain names and numbers; and (g) any and all similar or equivalent rights to any of the foregoing anywhere in the world, including any
              application, registration or renewal therefor.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(46)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>IRS</u>&#8221; means the U.S. Internal Revenue Service or any successor agency thereto.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(47)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Know-How</u>&#8221; means know-how, processes, procedures, instructions, formulas, chemical structures, chemical synthesis methods and intermediates, recipes, techniques, algorithms,
              routines, designs, design rules, specifications, trade secrets, information, knowledge, inventions (whether or not patented or patentable), databases, test methodologies, associated documentation, and any media on which the foregoing is
              recorded and any tangible embodiment of the foregoing.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(48)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>knowledge</u>&#8221; means, with respect to the Seller, the knowledge of any (a) officer of the Seller, and (b) employee or consultant of Seller who worked for Seller at any time
              [***] months prior to the date of this Agreement and who either alone or in concert with others has developed, created or invented any Product IP, in each case, after each such individual has made reasonable inquiry of all relevant employees,
              consultants and advisors of any Seller Party who any such individual reasonably believes would have actual knowledge of the matters represented.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(49)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Laws</u>&#8221; means all laws, statutes, ordinances, rules, guidance and regulations of any Governmental Authority, including all orders, judgments, injunctions, awards, decisions
              or decrees of any court having effect of law.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(50)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Liability</u>&#8221; or &#8220;<u>Liabilities</u>&#8221; means any liability, claim, loss, damage, deficiency, cost, expense, debt, obligation or responsibility, either accrued, absolute,
              contingent, mature, unmatured or otherwise and whether known or unknown, fixed or unfixed, choate or inchoate, liquidated or unliquidated, secured or unsecured.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(51)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Material Adverse Effect</u>&#8221; with respect to any Person means (a) any fact, event, circumstance or effect that (individually or when considered in the aggregate with all other
              such facts, events, circumstances or effects) results in, or would reasonably be expected to result in, a material adverse effect on, or a material adverse change to, the financial condition, business, or results of operations of such Person,
              or (b) the right or ability of such Person to consummate the transactions contemplated by this Agreement or the other Transaction Agreements, <font style="font-style: italic;">provided, however</font>, that with respect to the foregoing
              clause (a), any adverse change, event or effect arising from (i) changes or conditions generally affecting the industries in which the Seller operates, or the economy or the financial, debt, banking, capital, credit or securities markets, in
              the United States, including effects on such industries, economy or markets resulting from any regulatory and political conditions or developments in general, (ii) changes in GAAP, or (iii) changes in any Laws by any Governmental Authority,
              shall not be taken into account in determining whether a &#8220;Material Adverse Effect&#8221; has occurred; provided that, with respect to a matter described in any of the foregoing clauses (i) through (iii), such matter shall only be excluded so long
              as such matter does not have a material, disproportionate effect on such Person relative to other comparable entities operating in the industry in which such Person operates.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(52)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Material Contract</u>&#8221; has the meaning given to such term in <u>Section 3.14</u>.</div>
            <div>&#160;</div>
            <div>
              <div style="text-align: justify; text-indent: 72pt;">(53)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>NDAs</u>&#8221; has the meaning given to such term in <u>Section 3.12(h)</u>.</div>
              <div>&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(54)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Party</u>&#8221; and &#8220;<u>Parties</u>&#8221; have the meaning given to such terms in the <u>Preamble</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(55)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Patents</u>&#8221; has the meaning given to such term in <u>Section (45)</u> of this <u>Appendix A</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(56)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Payable Claim</u>&#8221; has the meaning given to such term in <u>Section 6.6</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(57)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Person</u>&#8221; means any person, limited liability company, partnership, trust, unincorporated organization, corporation, association, joint stock company, business, Governmental
              Authority or other entity.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(58)&#160;&#160;&#160;&#160; &#8220;<u>Proceeding</u>&#8221; means any judicial or administrative action, arbitration, claim, demand, hearing, investigation, litigation, proceeding or suit, whether civil, criminal, or
              administrative, and whether commenced, brought, conducted or heard by or before any Governmental Authority or arbitrator.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(59)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Product</u>&#8221; or &#8220;<u>Products</u>&#8221; means one or more of the products developed by the Seller and known as (a) Marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), (b) Dalcinonacog alfa
              (&#8220;DalcA&#8221;), and (c) CB 2679d-GT.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(60)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">&#8220;<u>Product IP</u>&#8221; means any Intellectual Property that (a) relates to the Products, or (b) in any
                manner, in whole or in part, relates to, is used in (or held for use in), or is necessary for the development, manufacture, commercialization, marketing sale, offer for sale, import, use or regulatory approval of a Product, including the
                Assigned Patents and Assigned Trademarks.</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(61)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Purchase Price</u>&#8221; means $6,000,000.00.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(62)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Purchased Assets</u>&#8221; means:</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(a)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">the Assumed Contracts;</font></div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(b)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">the Products;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(c)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">the Product IP;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(d)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">any designation granted by the FDA (including Fast Track Designation, Accelerated
                Approval, Priority Review, Orphan Drug Designation, and Breakthrough Therapy Programs) related to the Products;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(e)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">any FDA submissions related to the Products;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(f)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">records from communications with FDA related to the Products;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(g)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">data, records, and reports from clinical trials and nonclinical studies primarily
                related to the Products;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(h)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">data, records, and reports related to the development and manufacturing of the
                Products, including manufacturing of the Products used in clinical trials and nonclinical studies;</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(i)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">all of Seller&#8217;s rights under warranties, indemnities and all similar rights against
                third parties to the extent primarily related to any Purchased Assets; and</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 47.5pt; margin-left: 58.5pt;"><font style="color: #000000;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">all goodwill and going concern value of the Business.</font></div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(63)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Registered Product IP</u>&#8221; has the meaning given to such term in <u>Section 3.12(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(64)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Release</u>&#8221; means any release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, leaching or migration into, onto or through the indoor
              or outdoor environment or into, through or out of any property, including the movement of Hazardous Substances through or in the air, soil, surface water, ground water or property.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(65)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Representatives</u>&#8221;, with respect to any Person, means the Affiliates, directors, officers, employees, consultants, agents or other representatives thereof (including legal
              counsel, accountants, financial advisors, investment bankers and brokers).</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(66)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Resolved Claim</u>&#8221; has the meaning given to such term in <u>Section 6.6</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(67)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Restricted Party</u>&#8221; means any Person (a) that is the subject or target of any Sanctions, (b) identified in any Sanctions-related list maintained by the U.S. Departments of
              Treasury, State and Commerce (including the OFAC list of Specially Designated Nationals and Bureau of Industry and Security Entity List, Denied Persons List and Unverified List) or any similar list maintained by the United Nations Security
              Council, the European Union or its Member States, Her Majesty&#8217;s Treasury or any other relevant Governmental Authority, (c) located, organized or ordinarily resident in a jurisdiction subject to comprehensive territorial Sanctions (including
              the Crimea region of Ukraine, Cuba, Iran, North Korea, Syria, the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic), or (d) owned or controlled by any such Person or Persons described in the foregoing clauses.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(68)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Sanctions</u>&#8221; means economic or financial sanctions, requirements or trade embargoes imposed, administered or enforced from time to time by any applicable U.S. Governmental
              Authority, including the Office of Foreign Assets Control (&#8220;<u>OFAC</u>&#8221;) and the U.S. Department of State,<font style="color: rgb(255, 0, 0);">&#160;</font>the United Nations Security Council, the European Union and its Member States, Her
              Majesty&#8217;s Treasury and any other applicable Governmental Authority with sanctions jurisdiction.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(69)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller</u>&#8221; has the meaning given to such term in the <u>Preamble</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(70)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller Account</u>&#8221; has the meaning given to such term in the <u>Section 2.3</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(71)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller Balance Sheet Date</u>&#8221; has the meaning given to such term in <u>Section 3.4</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(72)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller Financial Statements</u>&#8221; has the meaning given to such term in <u>Section 3.4</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(73)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller Group</u>&#8221; has the meaning given to such term in <u>Section 8.16</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(74)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller IP Law Firms</u>&#8221; has the meaning given to such term in <u>Section 8.16</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(75)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller Party</u>&#8221; means the Seller and any Subsidiary of the Seller.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(76)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Seller Rep Breaches</u>&#8221; has the meaning given to such term in <u>Section 6.2</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(77)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Service</u>&#8221; means the services performed by the Seller for any other Person.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(78)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Settled Claim</u>&#8221; has the meaning given to such term in <u>Section 6.6</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">[***]&#160;&#160;&#160;&#160;&#160; [***]</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(80)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Straddle Period</u>&#8221; has the meaning given to such term in <u>Section 5.3</u>.</div>
            <div>&#160;</div>
            <div>
              <div style="text-align: justify; text-indent: 72pt;">(81)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Subsidiary</u>&#8221; means, with respect to any Person, any corporation, limited liability company, partnership, association, or other Person of which (i) if a corporation, a
                majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, or trustees (or similar Person) thereof is at the time owned or controlled,
                directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof or (ii) if a limited liability company, partnership, association, or other Person (other than a corporation), a majority
                of the partnership interests, limited liability interests; or other comparable ownership interests thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a
                combination thereof; and the term &#8220;Subsidiary&#8221; shall include all entities which would be considered a subsidiary of a Subsidiary under this definition.</div>
              <div>&#160;</div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(82)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Tax</u>&#8221; or &#8220;<u>Taxes</u>&#8221; means (i) any tax or duty or similar governmental fee, levy, assessment or charge of any kind whatsoever imposed by a Governmental Authority,
              including all income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, ad valorem, value added, inventory, franchise, profits,
              withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, alternative or add-on minimum, or estimated tax, together with any penalties, additions to tax or
              additional amounts arising with respect to the foregoing or the obligation to file Tax Returns, and any interest on any of the foregoing, and (ii) any liability in respect of any items described in clause (i) payable by reason of contract,
              assumption, transferee or successor liability, operation of Law, or U.S. Treasury Regulations Section 1.1502-6 (or any predecessor or successor thereof or any analogous provision of Law).</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: justify; text-indent: 72pt;">(83)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Tax Return</u>&#8221; means any report, return, statement, claim for refund, election, declaration or other information with respect to any Tax filed or required to be filed with a
              Governmental Authority, including any schedule or attachment thereto, and including any amendment thereof.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(84)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Technology</u>&#8221; means materials, ideas, information, and other subject matter, including technical developments, discoveries, inventions, works of authorship, products,
              designs, concepts, specifications, documents, data, reports, notebooks, technical information, processes, Know-How, methods, protocols, compositions, instruments, tools, and other technology.&#160; Technology includes all results, analyses,
              analytical methods, manufacturing process descriptions and documentation of process changes over time, batch records, testing, validation, quality control, and CMC data, quality systems information, yield improvement information, and
              regulatory information, filings, and data.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(85)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Third Party Claim</u>&#8221; has the meaning given to such term in <u>Section 6.5(a)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(86)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Trade Laws</u>&#8221; means all applicable (i) Sanctions, (b) U.S. export control Laws (including the International Traffic in Arms Regulations (22 CFR &#167;&#167; 120-130, as amended), the
              Export Administration Regulations (15 CFR &#167;&#167; 730-774, as amended) and any regulation, order, or directive promulgated, issued or enforced pursuant to such Laws), (c) Laws pertaining to imports and customs, including those administered by the
              Bureau of Customs and Border Protection in the U.S. Department of Homeland Security (and any successor thereof) and any regulation, order, or directive promulgated, issued or enforced pursuant to such Laws, (d) the anti-boycott Laws
              administered by the U.S. Department of Commerce and the U.S. Department of the Treasury and (e) export, import and customs Laws of other jurisdictions in which the Seller has in the past five (5) years conducted and/or currently conduct
              business.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(87)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Trademarks</u>&#8221; has the meaning given to such term in <u>Section (45)</u> of this <u>Appendix A</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(88)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Trade Secrets</u>&#8221; means trade secrets and confidential and proprietary ideas, Know-How, concepts, methods, reports, data, customer lists, mailing lists, business plans, or
              other proprietary information that provides the owner with a competitive advantage or from which the owner otherwise derives value, monetary or otherwise, from such information not being generally known.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(89)&#160;&#160;&#160;&#160;&#160; &#8220;<u>Transaction Agreements</u>&#8221; means this Agreement, [***], and each of the other agreements, certificates, documents and instruments contemplated hereby and thereby, including all
              Schedules and Exhibits hereto and thereto.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">[***]&#160;&#160;&#160;&#160;&#160; [***].</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(91)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Transfer Taxes</u>&#8221; means any transfer, documentary, sales, use, stamp, registration or other similar Taxes and fees.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(92)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Unresolved Claim</u>&#8221; has the meaning given to such term in <u>Section 6.6</u>.</div>
            <div>&#160;</div>
            <div style="text-align: justify; text-indent: 72pt;">(93)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Waived Claim</u>&#8221; has the meaning given to such term in <u>Section 6.5(b)</u>.</div>
            <div>&#160;</div>
            <div style="text-align: center;">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: center; font-variant: small-caps; font-weight: bold;">[***]</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: center; font-variant: small-caps; font-weight: bold;">[***]</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div>
              <div style="text-align: center; font-variant: small-caps; font-weight: bold;">[***]</div>
              <div style="text-align: center; font-variant: small-caps; font-weight: bold;"> <br>
              </div>
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div>
              <div style="text-align: center; font-variant: small-caps; font-weight: bold;">[***]</div>
            </div>
            <div><br>
            </div>
            <div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
              </div>
              <div><br>
              </div>
            </div>
            <div style="text-align: center; font-variant: small-caps; font-weight: bold;"><u>[***]</u></div>
            <div>&#160;</div>
            <div> <br>
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div>
              <div>
                <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                <div style="font-weight: bold; text-align: right;">Exhibit 99.1<br>
                </div>
                <div>
                  <div>&#160;</div>
                  <div style="margin-right: 378.7pt; margin-left: 0.5pt;"><img width="198" height="65" src="image0.jpg"></div>
                  <div>&#160;</div>
                  <div style="color: #000000; font-weight: bold;">Catalyst Biosciences Provides Corporate Update</div>
                  <div>&#160;</div>
                  <div style="color: #000000;">February 28, 2023</div>
                  <div>&#160;</div>
                  <div style="margin-right: 10.8pt; color: rgb(0, 0, 0);">SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (&#8220;Catalyst&#8221; or &#8220;the Company&#8221;) today provided two corporate updates.</div>
                  &#160;
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z220fe84b58604458a39beb5865297998" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="align: right; vertical-align: top; width: 9pt;">&#8226;</td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: left;"><font style="color: #000000;">In connection with the Company&#8217;s previously announced asset purchase agreement with GNI Group Ltd (&#8220;GNI Group&#8221;) and GNI Hong Kong Limited (together &#8220;GNI&#8221;) to purchase
                                all of the assets and intellectual property rights primarily related to GNI&#8217;s proprietary hydronidone compound outside of China (collectively, the &#8220;F351 Assets&#8221;), and the definitive agreement with GNI and other minority
                                stockholders to purchase their controlling interest in Beijing Continent Pharmaceutical Co. Ltd., a commercial-stage pharmaceutical company (the &#8220;GNI Transactions&#8221;), GNI Group reported its Consolidated Financial Results for
                                its Fiscal Year 2022 on February 15, 2023 showing continued revenue and profit growth from pirfenidone sales in China for the treatment of idiopathic pulmonary fibrosis, which includes revenue of approximately $102 million
                                and net profit of approximately $23 million. A copy of GNI Group&#8217;s financial results is available on the GNI Group investor relations website:</font> <u>https://www.gnipharma.com/english/ir/</u>.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcbe515c85f114f75a8d0842fcf1163fb" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="vertical-align: top; width: 9pt;">
                            <div style="text-align: left; margin-right: 3.6pt; color: rgb(0, 0, 0);">&#8226;</div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: left; margin-right: 3.6pt; color: #000000;">On February 27, 2023, the Company signed an asset purchase agreement with GC Biopharma (GCBP) pursuant to which GCBP acquired the Company&#8217;s legacy rare bleeding
                              disorders programs including marzeptacog alpha activated (MarzAA), dalcinonacog alpha (DalcA) and CB-2679d-GT for a total of $6 million, $1 million payable on signing and $5 million payable on February 28, 2025, subject to
                              satisfaction of post-closing indemnification obligations. Once received, the net proceeds from the transaction will be distributed to holders of the contingent value right issued to Catalyst stockholders of record on January
                              5, 2023.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">About Catalyst Biosciences</div>
                  <div style="margin-right: 3.6pt; font-size: 8pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">Catalyst is a biopharmaceutical company focused on developing its recently acquired small molecule F351 (hydronidone) for the treatment
                      of fibrotic diseases including hepatitis B associated fibrosis and non-alcoholic steatohepatitis. The Company previously focused on protease engineering-based drug discovery and development to address unmet medical needs in disorders
                      of the complement or coagulation systems and has been monetizing these assets to distribute cash to its stockholders. Additional information may be found on the Investor page of the Company&#8217;s website at:</font><font style="font-size: 10pt;"> <u>https://ir.catalystbiosciences.com/</u>.</font></div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>
                  <div style="color: rgb(0, 0, 0);">This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as
                    amended (the &#8220;Securities Act&#8221;) concerning Catalyst, GNI, the GNI Transactions, and potential future payments and distributions from the sale of the Company&#8217;s legacy rare bleeding disorders programs to GCBP. These statements may discuss
                    goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Catalyst and GNI, as well as assumptions made by, and
                    information currently available to, management of Catalyst and GNI. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions that are predictions or
                    indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this communication include, but
                    are not limited to, expectations regarding the GNI Transactions; the potential of, and expectations regarding, GNI&#8217;s programs, and the potential for an additional $5 million payment from GCBP; and the distribution of cash to legacy
                    Catalyst stockholders. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results and the timing of events could
                    differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties as to the timing of the GNI Transactions; (ii) risk that
                    future payments from GCBP will be reduced by indemnification claims under the Company&#8217;s agreement with GCBP; (iii) risks related to Catalyst&#8217;s ability to manage its operating expenses and expenses associated with the GNI Transactions;
                    (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions contemplated by the GNI Transactions; (v) unexpected costs,
                    charges or expenses resulting from the purchase of the F351 Assets; (vi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the GNI Transactions; (vii) risks related to the
                    inability of the combined company to obtain sufficient additional capital to continue to advance the product candidates and preclinical programs of Catalyst; and (viii) risks associated with the possible failure to realize certain
                    anticipated benefits of the GNI Transactions, including with respect to future financial and operating results. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed
                    as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Catalyst&#8217;s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current
                    Reports on Form 8-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) as well as the proxy statement and registration statement on Form S-3 to be filed with the SEC by Catalyst. Catalyst and GNI can give no assurance that the
                    conditions to the GNI Transactions will be satisfied. Except as required by applicable law, Catalyst and GNI undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements,
                    whether as a result of new information, future events or otherwise.</div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0);">This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.</div>
                  <div>&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <div>
                    <div style="color: rgb(0, 0, 0); font-weight: bold;">No Offer or Solicitation</div>
                    <div style="color: rgb(0, 0, 0);">This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the
                      solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of
                      securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will
                      not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation,
                      telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.</div>
                  </div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Important Additional Information Will be Filed with the SEC</div>
                  <div style="margin-right: 7.2pt; font-size: 8pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">In connection with the proposed transactions between Catalyst and GNI, Catalyst intends to file relevant materials with the SEC,
                      including a proxy statement and registration statement on Form S-3 that will contain a prospectus of Catalyst. CATALYST AND GNI URGE INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME
                      AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CATALYST, GNI, THE GNI TRANSACTIONS AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the proxy statement and prospectus and other
                      documents filed by Catalyst with the SEC (when they become available) through the website maintained by the SEC at </font><font style="font-size: 10pt;">www.sec.gov</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">. In
                      addition, investors and stockholders will be able to obtain free copies of the proxy statement and prospectus and other documents filed by Catalyst with the SEC by contacting Catalyst Biosciences Inc. at </font><font style="font-size: 10pt;">investors@catbio.com</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">. Investors and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become
                      available before making any voting or investment decision with respect to the proposed transactions.</font></div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Participants in the Solicitation</div>
                  <div style="margin-right: 7.2pt; color: rgb(0, 0, 0);">Catalyst, GNI and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transactions.
                    Information about Catalyst&#8217;s directors and executive officers is included in Catalyst&#8217;s most recent Annual Report on Form 10-K, including any information incorporated therein by reference, as filed with the SEC, the proxy statement for
                    Catalyst&#8217;s 2022 annual meeting of stockholders, and Catalyst&#8217;s Form 8-K filed with the SEC on December 27, 2022. Additional information regarding the persons who may be deemed participants in the solicitation of proxies will be included
                    in the proxy statement and prospectus relating to the proposed transactions when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.</div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Investor Contact:</div>
                  <div>&#160;</div>
                  <div style="color: rgb(0, 0, 0);">Catalyst Biosciences, Inc.</div>
                  <div style="font-size: 8pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">Trisha Colton, Investor Relations</font><font style="font-size: 10pt;"><br>
                      <u>investors@catbio.com</u></font></div>
                  <div style="font-size: 8pt;"><font style="font-size: 10pt;"><u> <br>
                      </u></font></div>
                  <div style="font-size: 8pt;"><font style="font-size: 10pt;"><u> <br>
                      </u></font></div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0H!W8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!****CJ,6BBBK$%%)2T
M"N%%%% PHI,T9I7 6BBBBX!1113 ***,TK@%%%%%P"BBBBX!3>].I*=Q-"T4
MF:,TKC%HIA84;A1<=AQHIH.:=33)MJ)WIU)2T D%%%% PI!12U/4 HHHJ@"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* $I:**5@"BBBF E+110 4TTIJ)WQ42D-*XA?FCS*JO+@U%]H]ZY)UK,W5*Y
M?\RCS*H?:/>G>?[TE7'[)EWS*/,JCY_O2^?[TU7#V3+OF4>95+S_ 'H\[WH=
M</9,O!\T%^:IB;'>D,_/6I]N+V;+V_BD#YJGY_'6A9^>M-5Q>R9>W4;JI^?[
MT&?CK1[<7LV6&DQ4#W&.]4I[P+WK/DOO>E[?J=%/#MFPUWCO35N\G&:YR34<
M'K38M1^?[U+ZQ<ZE@]#KHYL]ZM(V:YNWOPV.:U[>X##K6U.K<X:M%Q-"BF*V
M:?72G<Y;!1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !112&DV UC@52G?!JS*V*
MSKA^#7'5G8Z*4;L@EEJJ93FF22?-BHR:\RK4UN>C3AH3^:<U)YIQ53=2AJR5
M4IP18$IS2F4U 3Q0&S3547*BP)33EDJH6P:>&I.J)P+1EIGG5"6J%GYI>U$H
M%SS32^8:K*W%/4T*J-Q1-YI%(\^$ZU7D;%5IYL(>:I5AQI7(+V\QGFLA[X\\
MU'?7/)YK$EN3D\UC.N>K1P^A?GO3NZTV.].>M9+S$U&DQW=:4:QW_5ERG7V=
M^<C)KI]/N]V.:\XANBI'-=5I%WG;S7;1K'E8O#:'>0/N6K(K,LI=R#FM)>E>
MK0G='S=6-I#J***Z3(*3-#4BFF.PZBBBD(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*8YP*>:@E/%
M8596*BKLAE?K67<R=:M3R8S6;,VXUY5>IJ=U*!78Y:BC'-*1Q7G5)-L[HZ$9
M-/4TW;FG 4D]"V*32@XI,4 9H3) FA6I2M 7FGN2Q6.!474U,5R*8$P:@$2)
MTJ3I2(M*_ IDMZD,IX-8]Y/C(S6E.^%-<S?S_.>:QG.QW82ES,HWTO6LAFW&
MKEP^^J6W!K%S/=ITTD&.*CQ@U.!Q3&7FE&9TI*UA5?!%;FF76UU&:P,8J]9-
MB1:ZZ-34XL523B>H:3/N1>:Z&,Y45Q6BS_*HS77P/E!7N8:IH?&XVGRR+!-*
M*;UIPKTHL\X1NE(M.-(!6G0KH.HHHI""BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH8#6/%5)WP*LN<"L
MZ[DXKAKS-J4;LH74N2:J;LT2L233!7C5I'ITXV0X#FE8<4HZ4[%<^YI<8HXH
MQS3L4N*:07&D<4**7%*!0@N&*,4\=*0#FFMR;B@4T]:<U,H:!$B]*CF; I<U
M6NI,+4O0<8WD4KN;"GFN6OI,R&MB\GP#S7/7#[I,UR5&>]@J=M2$FF$9IS=*
M11FL&>H@'2FD4I'-*1Q0!"]36SX<5$PIJ$AQ713>H5(\T;';:--\R\UW-G)N
M1:\WTB7!6N\TR7*K7LX:5SY+,Z5G<W5Z4ZHT/%25[=-Z'S["BBBM1!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ5*XDZUQUJFAK3C=E*Y?K6=(V35F>3K5/.6KQZT[GI4XV0J"@CFG45PRU-D
MIU-I<TX@(:6BDIR8D@I:2C-2F,=2TE!/%;P$(>:4\+2*:9*X"FM7HAVN[%"[
MDVYYKGKZ?=GFM/4)^#S7-W$N6-<=69[6#HW5R%VJ(TI.:2L(ZGK15D*@YJ<#
M%1(.:FI21$V&*8W(J3M3.]96U,5*S(=M1L.:M'%0L.:TBSIC*Y-;-AA74:3/
M@CFN2C;#5MZ=/AAS7?AI:G'C:?-$]%L9-P%:\?2N;TF;<HKHHCE:^AP\M#XG
M%0Y96):2@T"NLX^HM%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO<B]#YQJS%HHHJQ"444M,2"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "T4F:6
M@ HI,T9H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **3=1F@!:*3-+F@ HHI,T +1110 44F:7- !
M1129H 6BBDS0 M%)FC- "T444 %%%% !1110 4444 %%%)F@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BDS2T %%%% !1110 4444 %%%% !1110
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MZJWVYOF[T >L6&HB4CFNCMGW+7EN@ZEN*Y:O1-,N0Z#F@#7HI <BEH ****
M"BBB@ HHHH **** &N<"LC4)]H/-:DYPE<MK5UL5N: *TFI!&QNJ[97_ )K
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M/'>@#L/#]^=R#->JZ1*7A6O$M"FVSH,U[)H#AK=.: .F7I2TB_=%+0 4444
M%%%% !1VHHH B;K4B]*0KS0>!0!E:M+L0UY3XFOB'8 UZ1K\VV-N>U>.^([C
M=*PSWH Q6F9YLUV/A;>95SZUQ]C$99QQ7I/AFQVE3B@#T#30?+7Z5K#I5*SC
MVH/I5T\"@!&8 <UCZE=K$IYJW=SA%/-<-XAU78K?-0!2UO55"MAJ\\O]0DDG
M."<4_4]7:28KNZFH[>V,Y#8SF@"KNE?UJ_:02L.AK7L=(\S'RUTMGH(P/DH
MY-;:7'0TU[2;T->AQZ -OW/TJ1?#RL?N4 >;K:38Z&J5Q!.'Z&O5F\.JH^Y5
M&?PVI.=E 'E[1S*,X-(DTJ'G-=]=^'PJGY/TKF-1TWR2<+0 RRU-T<<FNVT?
M600H+5YJV8CFK-EJS12@;J />-/OTD5?FK91PPXKRO0]9+[1NKT/3+CS4'-
M&F>E4;S.TXJ]UJ&:/>* . UU7(; KS35X93*>#7M>I:<) W%<9J&AAY#\M '
MF444XDZ&KP2?'0UVD?AP;L[/TJY'X=!'W* //3'-GH:7RY\=#7>2>'P&QL_2
MIE\.C9G9^E 'GGDS>AJ58IMO0UWJ^'03]S]*<_A\*A^3]* /,+@S(QZU5^U3
M*>]=OJ.C!2?EKG;G3PI/% %*&>63UJXL4S#H:NZ7IPD8<5UUGH = =E '"BW
MF!S@TXQSXZ&O1/\ A'!_<IC^'0/X/TH \X:.?/0T[R9]N<&O0U\- _P?I3V\
M-C;]R@#S-HY\]#3X89MXX-=_)X< /W/TI8?#P!'R4 9^B12!ER*]*T;=M7-8
M>G:0(V'RUU]E:B-!Q0!HK]VEH'2B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *0TM-/2HF] 0QS\M9\S\U:E? K-F?K7!6GH=5&!4N352K,AW57/6O
M%K2]X].&B%6I*:HXI]9H&%%'>G <50KC:,T&DI,!G>G]J3%**!L6F-UJ2FD9
M%4D),CZU+"G-1J/FQ5V&/I732@*<[(N6RUI)TJK;IQ5Q1Q7J4(GEUI78HIU-
MI17H+8YT+1110,**** "BBB@"M<+E#7(ZQ$2&XKLI1E37.ZK#E&.*X<5"Z/1
MP,^61YOJ$6'-48ABMW4H?G;BL5AM-?-5XV9]EAI<T1&ZTY12 9J1:X^IU-A2
MYI6&*;6J)"D-.%##BIF RD-/ IK"L7N-$1I\9P:1A30<&NBD[,;5T;FG2?O%
MKO=*ERBUYM8RXE7FN\TB7Y%YKV,/+8^=S.EH=;&<J*DJK ^5%61TKW*3NCY:
M2LQ:***V)"D[TM)0)BT4E+20PHHHI@%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %-8XIU1O0 ,V$)KG-5U'RU(S6U<R;(&^E>=^(;XJS#
M=0!BZ]J_WOFKBY[@W#]:GU6Z:5V&:CTVR:9AQF@"2SM"[CBNNTK3<XXJ72M#
M) .VNOT[2O+ ^6@"&RTOA?EKH+:Q"KTJU;6P4#BKZ( * **6H':FSVXQTK2V
MBH95H P+BP#J>*Y35M(R&^6O1?*!7I67?60<'Y: /%]1TDJ6XKGID-O)^->O
M:GI&[=\M<!K>E%&)VT ,T;4"DBC->HZ!J.]5&:\4@8P7 &<<UZ!X;O\ !7YJ
M /7(YLJ*LH<UAV-SYJ+S6S%TH EHHHH **** "BBB@ HHHH #TK/OIML;5?;
M[IK!U:3;&W- '&>(Y]ZL,UY9JT.^1J[W6;G=(RYKD[J'>3Q0!S4$6R5?K7>^
M'I=I6N9^Q'=G%;>E/Y4@% 'KVB3;T49KIUZ"N&\.3YV\UW$;944 /HHHH *0
M]*6B@"I<P[UZ5B7.G!B>*Z4C-0O$#VH Y7^R >=M/33PIQMKIQ"N.E0& ;^E
M &,;( =*060/:MMH1CI0D(]* ,/[$,]*<UB-O2M@P#=TI[0C;TH \_UNW"*W
M%><:D<7&/>O6?$<6$;BO)M67_2OQH T-*&6%=WI-OY@7BN'T5<LHKTS0H/E4
MXH NK8#'2F_V<-W2MY81CI2^2/2@#!.G@C[M*ED$[5N^2/2HWA'I0!CFR##I
M4;:</[M;R0C'2G>2/2@#(M;$(>E:T,6WM3TB [5,HQ0 JC I:** "BBB@!K'
M KF];DPC5T$K8%<?XAN=B-S0!YSXBFRS+FN$EM\SEL5UFKR^;.1[UF_9,C.*
M (]-78RUZ9X;GV[!FO.H8_+85V6@3X=.: /7K%MT -6JR=*GW6ZC-:H.10 M
M%%% !1110 4444 %%%% %>[&8C7!>(A@-7?7/^K-<'XD^ZU 'F]ZFZ7\:W/#
MB8N4K%NW E_&MSP\X^T)0![!IH_T1/I5VJ&FOFU7Z5?H **** "BBB@ HHHH
M 8S8I'^9*''-+CY: .7U^T\V)N.U>2Z]9>4[''>O<-0B#H>*\Q\56F-Y H X
MC3I?+NU^M>O^'+O,"#->*A_*O1]:]+\-WN(TYH ]3@?<HJ>LK3KCS%7FM6@
MHHHH **** "BBB@ J"Y?8F:GK.U239 3[4 <MKUSN5AFO(M?DS=8]Z]!UB\Y
M<9KS;53YMZ/K0!L:!9>8ZMBO4]#L]B+Q7&^%;/=&AQZ5Z;86XCC7B@#3A7"B
MEG;;&33EZ53U";9 W- '/ZOJ&P,,UYCXDU/<6&ZNEUZ^^9AFO.-6D,TAY[T
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M&YK8F.U37'^([G;;OS0!YYKE[NF<9KFMAFE'UJ;4;DR7C#/>K6G6S2R+QWH
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MLBQ@WS#B@#I?#>G[V7BO4-+M?)4<5ROA>TP5XKT&&':!Q0!8B'%2TU1@4Z@
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MEM@2DX^M>K>%KS"*":\NBA*3].]=KX>E99$% 'LME)OA!JY6-I,FZW6M@=*
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M(O2EH **** "BBB@ HHHH **** (F'-2+THQ2T %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** *%^V(J\[\0R\/7H.I\0FO-/$+_?H
M\WU$[KX?6NY\++D)^%<'>'-\/K7HWA2/Y$- 'I.F)B-?I6P*SM/7$:_2M*@
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MT9KSDKY<M=;X9N?WBC- 'K%JV5%6JSM.?<@K1H **** "BBB@ HHHH @NO\
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MZ@?2@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFR7$:U>JK:#]TOTJU0 4444 %%%% !1110 4444 %%%% !56ZB#KC%6J0C-
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M>(^K5YSJ'^M->C>(^K5YSJ'^M- &UX:^^OUKUS1O]0/I7D?AK[Z_6O7-&_U
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M ULI]J\)T*ZQ=H,]Z]HT6?=:ISVH W:*:IR*=0 4444 %%%% !1110 4444
M<CXH^XU>/ZN!]J_&O8/%'^K;Z5XYK#8N_P : -+1/]8M>J:!]U:\KT/F1:]4
MT#[JT =4O2EI%Z4M !1110 4444 %%%% !2&EJ.0X% &=J,H6!N>U>1>*)<S
M-]:],UFXVQ/SVKR+Q#/NN&Y[T 9NEKYEU^->FZ#; !>*\YT-,W(/O7J^AQ?*
MO% '66*[8Q5NH+882IZ $/2N=UF$,C&NB/2L75!E&H \@\3QE0]<_P"'9-EY
M^-=?XH@^1SBN)TMO*NS]: /;-!N 47FNO@;<F:\ST"\^X,UZ+I[[X0: +M%%
M% !1110 4444 077^KKA/$GW6KN[K_5UP?B3[K4 >;WAQ+^-;WAWFX2L"]_U
MOXUN>'6_TA* /8=-_P"/5/I5^J&F_P#'JGTJ_0 4444 %%%% !1110 4444
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M+E5KZ+"3/F,RI6.B'2EIB'(IU>JM3YQZ"T444P"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#+UC_ %!^E>5^(1EGKU36/]0:\LU\
M_,] ''(,7B_6O4?#"_NDKR]3_IB_6O4_"Q_=)0!WENN(Q]*L5%#_ *L?2I:
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MU3U7D^]3@]31:Z&KI[8<5W.CS9"\UY[9R885V>BR\KS7N829XF8T[Q9W,+9
MJ:J5L^0*O+7O4Y71\?4C9BT445H0%%%% !1110 4444 %%%% !1110 4444
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M5^- &AH7WUKU30?NK7EFB?ZQ:]3T#[JT =4O2EI%Z4M !1110 4444 %%%%
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M%>6H/]+7ZUZEX67]VE 'H4'^J6I:B@_U2_2I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "LK47VQM6K6!K,NV-OI0!P6O7'SL,UQ%X-
MSDUT&N7.;@C/>L5(_.:@#L/ Z8*\5ZG;_=%>>^#[7R]O%>B0K@"@"<4M(*6@
M HHHH :PR*Y/Q"F8W^E=:W2N:UQ-R-0!XQKD.+ECCO2Z%-MN ,]ZO^((<.QQ
M6%I<FR\_&@#V_P -R;HU^E=*>M<5X5N,HG/:NS4[J )UZ4M(O2EH **** "B
MBB@ HHHH Y'Q1_JV^E>.:PV+K\:]C\4?ZMOI7CFL+F[_ !H T=%/SK7J7A]L
MA:\MT4?.M>H^'A@+0!UPZ4M(.E+0 4444 %%%% !0:*0]* (I'VBN<URYQ&W
M-;MV=J$UQ'B"ZPK#- 'F/B9_,N_QK0\/19V\5BZQ)YEV/K75>&8=P3B@#T30
MHMJJ<5UB_=%8.DQ;8UXK>'2@!:*** "D/2EHH S-0C_=FO,O%47#<5ZQ=)OC
M(KSWQ59_*QQ0!Y2I\NX'UKT?PQ>81!FO/[J K/G'>NG\/3['5<T >PV,V^-:
MT1TK!TB3=$M;HZ"@!:*** "BBB@""Z_U=<'XD^ZU=Y=?ZNN%\1#*M0!YI>_Z
MW\:W/#K?Z0E8E^,2_C6UX=7_ $E* /8M-_X]4^E7ZH:9_P >J?2K] !1110
M4444 %%%% !1110 4444 %%%% !5:[3="WTJS3)1E"* /*O%=GN5SBO/;2/R
M+MC[U[+XCL=\+'%>67EMY-PQQWH TX-1V*.:)]1WKC-<S-=^6<9I8KHOWH N
M3_O6KK_!]MAEXKF+&'SW QFO1?#5EY6TXH [6S3$?X59V\U';C"U/0 4444
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MQ,;P9Z#I$V0O-=/;ME:X32;C&WFNSL9-T8KZ/"3NCXS&T[.YH44@Z4M>FCS
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R=7(\@U
MYAKWWGKTO52?)/TKS37NK4 <:/\ C\7ZUZEX6/[I*\MS_I:_6O3_  L3Y:4
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MHTE?WZT_61F8_6G:0/WJT >GZ /D6NN7[HKD=!^ZM=<OW10 M%%% !129I:
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M?++^-;/AX9N4- 'K^F?\>J?2K]4--_X]4^E7Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KFO$YQ ?I72USGB49@/TH \BU/F4_6GZ7_KEIFK_ "RG
MZT_23F5: /3M!^ZM=<OW17(Z#]U:ZY?NB@!::W2G4A&10!&IYJ6F!<4^@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6H+F$U=J&X7<F* /*_
M$]OG=Q7G<R^7.,>M>L>+(-J,<5YA=1YDS[T =3X;E^9>:]4TMR8EKQSP]-BZ
M5<]Z]DTE?]&0^U &L.E+0.E% !1110 4444 %1S?ZIOI4E1S?ZIOI0!Y]XBZ
MM7F^I_ZQJ](\1=6KSC41F1J -CPL?WB_6O8-'_U ^E>0>&!AU^M>O:-_J!]*
M -6BBB@ HHHH **** "BBB@ HHHH **** "D-+3&.!4R=AH1VP*S[F3@U8D>
MLVZDYKBJU3:G3U*,SY:HJD89.:3;7DUI79ZD-$(HIU &*6N1ZE-C"*1:?BD
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MMKPZ<7*"L:[XD_&M?P\/]*3ZT >Q::/]%3Z5>JEIO_'HGTJ[0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<]XC_P!2?I70USWB/_4GZ4 >1:RN93]:
M;I38F45)K!_>'ZU#I@_TA: /4M ^XM=>OW17(:!_JUKKU^Z* %HHHH ****
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MYU^M>N:-_J!]*\@\+G,B_6O8-'_U ^E &I1110 4444 %%%% !1110 4444
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MH-KD*<4 =5IUN/+!Q6B81CI26<>R,"K6* *JP@=J?Y0]*GQ1B@"NT((Z4U8
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MYH ]RTB_!A'S5NQ7 ;O7E>C:UB)1NKK].U,2D?-0!V$;9J6J%M-D#FKH;(H
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MZU-\K#-=9<_ZHUPOB&3RU8T >:>)Y?G;ZU2T-2\JT[67\^4CWK2\.6>9$XH
M])\/0XB4XKM(%P@K!T2VVP+Q71(,** 'T444 %%%% !1110 4444 %%%% !2
M'I2TAH H7D>]37E'C6'8S<5[!*N0:\T\:VV\MQ0!YE;<3 ^]>@>&IOF49K@W
M7RI?QKI_#-UFY49[T >QV!S&OTK1K*TQLQ+]*U: (+K_ %=<+XB.%:NZNO\
M5FN%\1#*M0!YM?G,OXUK>'I,7*"LC4.)?QK2T'BX4T >S:8W^BI]*T0:P]*F
MS;H,]JU3*%'6@"8M2;JIO<<]:;]H]Z +X:@M5$7('>@W(]: +NZE#50^T>]*
M+D>M %XM2;JI&Y'K2?:/>@"_NI-U4OM ]:<L^>] %S=2%JH/<A3UIT<^X]:
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MQ[:6)-JXJ6F,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0TM)4R5P(I%RIK OXLD\5T;#BLR[@R":XZT+HZ\-4Y9'%WJ;2:S@>:Z#4;?
MKQ6!(NPFOFL9#4^BP\^9 #3P<5$.:DZBO':]XZV/#9I"<4@XI<9KJI$,0GBF
MYS3B.*:!BMVREL-/%.3K2,,TJUB]QO8GSQ4;=*>.E-(R*ED(HS"J4E:<J<51
ME3%4==*13;BE44K4@.*=SJZ#Z:QI>U,)J6"0A.:8QIW:HVZU:+2"F,?F%2*,
MTUUYKH@["GJK&QI4V'49KO\ 29,JM>9V+[9!7=:/<_*HS7HX:>I\]F-.ZT.U
MC/RBGU4MI-RBK=?0TW>)\M)684445H2%%%% "4M)2TD 4444P"BBB@ HHHH
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MXJ5:0(=1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %5;N/>M6J0J#0!R-[8Y8\4RUL,.#BNCN+<,>E)%;@=J %M(=BCBKXZ4Q%
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MG8K54[$.9$B =JEQ1BEK5*Q#=PI#2T4Q""EHHH **** "BBB@ HHHH ****
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M8HH K^0*;Y(!JU3<<T (JX%/HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %)FD;I3%/- $M%%% !29I:C<\T 244U.E.H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBD;I0 9I:B4\U+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !2$XI:8YH <#2TQ*?0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !28I:2DV M%%%, J.5<BI*:W2IFKQ&MS#OX00:Y#4(<.:[J
M[3(-<MJ,'S'BOGL;2/;P%36QSX7!I2:FF3:*J!LM7A25F>['WE<G6G \TU*=
M0)D@Z44U32L:5]2+#A2,>* >*83S5 D*M#4@H-4D/J(:KS+Q4W>FR#(JBXZ,
MRY5JJ>#5^9:H./FJ&=L'=#U.:5A3%IQ-)*YJ-S2-TIIZTK?=ILJQ!(<FM#3Y
M"KK6:>M6[0XD6MZ+M(C$Q3@>@:-*3MKL+=@4%<+H\F M=C9R945]'A9Z'Q6/
MA[QH4M(*6O33/*"DS2TUJ8(=12"EH *2EI*E@+1115 %%%% !1110 4444 %
M%%% !1110 4444 %%%,+<T /HI,\49H 6BFD\THH 6BBB@ HHHH **** "BB
MD)H 6BDS29H =1110 4444 %%%% !1110 4444 %%%-)H =13"W%1^;S0!/1
M48?-/!H 6BBB@ HHHH **** "BBB@ HHHH 0C(IJK@T^B@ HJ)WQ2"2@":F,
M,TH;-#'% "J,4M1;Z%?)H EHHHH **** "BBB@ HHHH **** "BBDS0 M%)G
MBF[J 'TAZ5&SX-.W?+F@ "\T^H5DRU2B@!:*** "BBB@ HHHH **** "BBF%
MJ 'T5%OYJ0'(H 6BBB@ HHHH **** "BBB@ HHI": %HIH:G4 %%%% !1110
M 44A.!2*V: '44TFE% "T444 %%1E\&E#9H ?1110 4444 %%%% !1110 44
M44 %%%% !1129H 6BF%N:<#D4 +1110 4444 %%%% !36&:=10 U1BE-+4;-
M0 ;J-U1L<4W=S0!9!I:C1N*'?:* )**BC?=4M !1110 AZ4S=\U//2H]OS4
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M4 %%%% #2V*A>X"TDC8%8M_=>6#S0!HMJ*J>HH&HIZUPUWJQ63[U-36./O4
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M %%%!Z4 1ROL&:IF]5>])J4WEQ$YKDKG4]K'YJ .I^VAGZU?A?<M<+;ZF&E
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MNGJ*/[63U%><?VTW]ZGIK#9^]0!Z(=60=Q4+:NF?O"O/Y]98?Q56_MML_>H
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M2"W+]JNIIY8=* ,I96W5=AN"N*M?V61SBJ\]N8NU &E;:CL(^:MRRUOD#?\
MK7!R3F.HX=5*2=: /:-/U0/CYJZ.UN XZUX[HVLY*_-7H&DZCO"\T =BIR*6
MJ]O)O058H **** "BBD/2@ )P*H7LX1#S3[F?8#S7+ZUJGEQGYJ %O+]1N^:
MN2U35]I(#5F7^O89ANKE[[53*_6@#7NM3+D_-6>UPTAJA#*96Q6M;VA8 XH
MK>:R4^.\96ZU<>P)'2JDMH4[4 :=KJA7'S5T.GZWM(^>N >0Q&EBU,QL.: /
M;],U02@?-^M=+;RAT!S7C&B:W\RC=7I6D7_FQKS0!TPZ44Q&RHI] !1110 4
MR4X2GU%/_JS0!S.MW'EQMS7E^M:H5F(W=Z]#\0M^[:O'?$,A6X/UH [3P_?%
M]O->CZ7-N0<UY%X6?*K7J6C-\JT =2OW12TU/N"G4 (>E5I3P:LGI56XX4T
M</XDN-C-S7%W-]@'FNC\6S;6:O/+NYY(S0!;;426QFF/>L.]9<;%GJ\L!<4
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M15UYKT[0+S*KS7C=E*4=:]#\/7N HS0!ZW:3;HQ5RL'2Y]Z+S6ZO2@!:***
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MZDBL.UC,][^->D^'M+P$.V@#H]#TD%%)6NIM]/51TINEVWEH.*V%3% %9;0
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M]E'I1]E'I5NB@"I]E'I1]E'I5NB@"G]D7/2E^RCTJW10!4^RCTI#:#/2KE%
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M#M[5<'2D50!3J "D8X%+4<A^6@#&UF?9&>:\E\37WS,,UZ3XBEVQ-SVKQWQ
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M<YD>@#-T+YI1]:]3T(8"UY9X?XE'UKU30^BT =M;?ZH5-4-M_JA4U !1110
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M:1/NBEH *I7WW#5VJ5]]PT >3^+L^8?K7*P_>KK?%@S(WUKE(A\] '9^$_\
MCX7ZUZM#_JE^E>5^%1B=?K7J<!_=K]* ):*** "BBB@ HHHH **** "BBB@
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M 'FE[_Q_K]:]*\)X\M*\RNSF^'UKTCPFWR)0!ZC9_P"K6KXK.M#^Z7Z5?4T
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M0 4444 %%%% !2-TI:0]* *4J\UPGC$ 1MFO0'6O/O'61$V* /-"09OQKJM
M(\U:XU7/F_C76: Q\Q: /6-+/[I:UI/]4?I6+I#9C6MMO]6?I0!P/B2#=NXK
MR_5(O+E8U[#KD&Y6.*\J\10E"Q H /#]T%E7GO7KV@70:$<UX'I5PT4XSZUZ
MUX9OP8UR: /14;(I]4;6X5T'-70>* %HHHH **** "BBB@ HHHH **** $Z5
M6NS^Z-63TJC>$[#0!YKXU_U35YW8#]]^->A^-#^Y;Z5Y_IW^N_&@#OM QN2O
M3-/_ -0M>8Z'GS%KTW3O^/=: -$=**!THH **** "BBB@ HHHH *:RY%.HH
MKF!2>13E@4=JEQ2T -" 4ZBB@ J.4?)4E-D^[0!Q_B'_ %35X]X@_P!>?K7L
MGB48@;Z5XQKIS.?K0!M>&NBUZCHP.U:\O\,_PUZIHP&Q: .E3[@IU(GW12T
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M_-LX7.* /;M)U,.0-U=3',"@.:\8T;6MI4[J[FQUL.BC=0!VBN#WJ0&L&#4
MV.:THK@,.M %VBH5D![U(#F@!U%(3Q4>_F@"6BD!S2GI0 44S=S3Z "J-\,0
MDU>JGJ'_ ![F@#RKQB^485PE@<3?C7;^,.C5Q&GC,WXT >A^'DW,IKTVP7%N
MM>;^'!@I7I=E_P >ZT 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "FO
M]VG5%(>* .6\3_ZAOI7BVN?\?!^M>T>)O^/=OI7B^N?\?!^M &YX:Z+7J.C-
M\JUY;X:Z+7J&C=%H ZI/N"G4U/N"G4 %4K[[AJ[5&^^X: /+O%29=JXY.)@*
M[/Q2V&:N+7F?- ';>&/EE4^]>GVDFZ-?I7E_AP_.M>DV;81?I0!?+<T\&JS/
M3?/ [T 6\TTMS5;S_>FF;WH N@\49J@+D>M2"X'K0!;S03Q5)KD#O2K.&[T
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M;?ZH5-FL^WG'E#FGM<@=Z +9;FEW<5G&Y'K2_:ACK0!?#4%JSQ<CUIXG![T
M7 U/!XJB)>>M*]R%7K0!;9A3E.:R_M8)ZU>@?<M $]%%% !44R;EJ6D/(H Y
M76K7Y&XKRGQ%9_.QQ7M>IP[T/%>:>(K/A^* /.[>Y-O<!<]Z[_P_J6-OS5Y[
M>PF.XS[U?TW4_)8#/2@#W>POQ(B_-6HDX)ZUYAHVN9"_-746^JAB/FH [)'!
M'6G9K#M]0##K5];D$=: +9;FG \54\W/>GK)0!9HIBMFES0 ZBD%+0 4444
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MVWBSHU<98_Z[\: /0O#_ -Y:](L6_<+7FV@'E:]%L3^Y6@"_10.E% !1110
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M:O0:LR]6_6@#U*/5E_O5.NI#KFO-8M9.1\WZUH1ZS\GWOUH ]$@U$,>M6Q=
MGK7GMEK(W\M6W%JJL1S0!V43[ES4E9=A>*\8YK25PPH =1110 4444 %%%%
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M1JV:DH **** *6H?ZDUY?XI."U>H:C_J37F'B@9+4 <,I_?#ZUW'A@_O5KB
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M]RBIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/UJSX<.)$JMK_$I^M3^'AF9,4 >RZ&?W"UTJ'Y17,Z%_Q[I72Q_=% $E%%%
M!1110 4444 %%%(>E $<AXK@?&G^K:N[DX%<'XR^:-J /*I?]?\ C73^'_\
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M7[79<$X[T :7AZ^*NHS7K.A77F(N37B&BR[+A1GO7KGAR;Y$YH [L'BJM]S
M:=&^0*9>']P: /+O%P^5JX.U_P!?^-=WXQ.$:N!LSF;\: /1?#O\->D6)_<B
MO-?#S<K7I-A_J5H T.U% Z44 %%%% !1110 4444 %%%% !1110 4444 %1O
MTJ2H9#0!R_B;_4-]*\6US_CX/UKVCQ-_Q[M]*\7US_CX/UH V_#71:]0T;HM
M>7^&NBUZAHW1: .J3[@IU-3[@IU !5*^^X:NU4O!E#0!Y;XI4;FS7&)C[0/K
M78^,&V.U<-$Y-P* /0_#2@LM>D6L?R+]*\W\*G+K7IUN,1K]* )=M)Y8I]%
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MA 9@4^U 'I%H/W(JU5.T;]V!5R@ HHHH **** "BBB@ HHHH **** "BBB@
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M[&'GJ<V-BG%GI>GOE5K5'2L/3G_=K6RAR*]ZE/0^*Q$;2'F@4M)72<HM%%%
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M=[5AZ4,1K6X.E #"O-/'2EHH **** "BBB@ HHHH **** $/2F!>:D-,!YH
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M\UXOX>;;-^->J:)/]T9H ] @.8Q4M5K,[H0:LT %%%% !1110 4444 %%%%
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M#S:3_C['UKT3PP?D2O/9AB\'UKT'PQ]U* /3=-^XM:W:LG3?N+6MVH ****
M"BBB@ HHHH *CE&5J2FOTH Y[4E^5L^E>+^,U'VH_6O:M7("-]*\7\7D&Y/U
MH 9X=X*UZOH9.Q:\F\/G]ZHKUW05_=I0!U4/W14]1QC"BI* *.H_ZDUYEXF_
MCKTW4?\ 4FO,O$W5J .'/^N'UKMO#&?-2N)_Y;CZUW7A@#S$H ]2M?\ CW7Z
M5/4-K_Q[K]*FH BF&4-<OK$8VM752?=KG=73Y&H \8\7#$K?6H?#CXD6K/C%
M?WC?6LS0GVRK0![5H;9@6NI@SM%<;X=DW1H*[:$#8* ):*** "BBB@ HHHH
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M FHHHH **** "BBB@ HHHH **** "BBB@!#TK$U?/D/]*V6Z5D:H,V[_ $H
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M1S7JX>9\YF%.ZN=$IR*?44396I!7MT]CYYJS%HHHK004444 4+[F(UYKXH&
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MVXV1MS7E6OW/FNPS0!S]L-UROUKU/PO#^[4XKS?3(-]RO'>O8/#=IMME..U
M'6V:XC6KU5+?@ 59)Q0 ZFL>*8SX%56N1G&: +BG-/JM"^ZK- !1110 4444
M %%%% !1136.!0!7NI-J&O._%$F4>N[O&RK5YUXF?Y7H \QE.[42/>NVT&/
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M\.QXVUYUH%ONF''>O5="M]H7B@#M[+_4"K-06HQ$*GH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*
M#12TK 4;N/<IKF=0AY/%==*N5-85_!G/%>3C:5T>C@ZO*SC;B/:QJNAR:U+V
M'DUEE=AKY:O3M(^CISYD3J:<1Q4:'-29XHCHBF,HI2,4 47&+CBCK2TF,4A
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MBEE '6J370"YS5.:]!!YH L7%V%0\UQ^N:H C#=4NJ:IY:,-U>?:UJY8L-U
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M!8E,UYZ\UW>A6)RAVUS>AV/G2JV.IKU/1-+PJ'% '2:%!LB'%;P&!5.R@\I
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M)5)% %'2M'9I 2M>I>&-.\K;E:H:1I2X7Y:[C2[,1 <4 :T$851Q5BD48I:
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M'^*J\^M#81NK@SK!_O5 ^J,W\5 '17^JYS\U<CJD[3DX-.FN7D'6HHX6D/-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5+Z&D\J7T->@_P#".#'W*:OAT$_<H X#RI?0U"Z39Z&O17\.@?P5$?#@/\%
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M4 %%%% !2$9%+10!4FAW#I6=-9 GI6W@&F-&#VH QXK/:>E:4,>T5+Y8]*D
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MHH 3;3=@I]% #=M*!BEHH **** "BBB@ HHHH **** "D(S2T4 -VTN*6B@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1[N:D[5
M$5^:@"0=*6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "DH-)3);%HHHH&&:*3%% M1U%%%(H**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,444 +
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
6 4444 --)113('"EHHI%(****!G_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
